Patent Grant
11978559
Subsequent to a procedure (e.g., surgical/invasive procedure to replace a knee or hip), the location of the procedure, or near or distal thereto, may become infected. While some infections may naturally heal without treatment (or without significant treatment), other infections can spread throughout the body, and if left untreated cause, for example, staph or other infections, sepsis (septicaemia), peritonitis, and other life-threatening, life-quality-threatening or other serious medical conditions. For example, a user may be exposed to staphylococcus bacteria during or after a surgical procedure, leading to a staph infection that can spread throughout the user's body, i.e., to a location (or locations) other than the location of the procedure. These infections, if left untreated, can cause a range of health issues to the user, from minor skin problems, to amputation of the user's infected limb, to even death in severe cases. Such health issues may occur temporally, geographically and/or anatomically proximate manners.
To avoid such health issues, some medical professionals schedule routine: check-ups, wherein the check-up is based on the type of procedure to the user. In between the routine check-ups, medical professionals may rely on users to detect and “self-diagnose” any health issues resulting from the procedure and to contact them (i.e., the medical professionals) for further diagnosis and/or treatment. In some instances, non-infected users may self-diagnose the health issue incorrectly and schedule unnecessary appointments with their medical professionals, resulting in inefficient uses of medical professional resources.
In some instances, such as during the COVID-19 pandemic, medical professionals may schedule remote medical assistance. Remote medical assistance, also referred to, inter alia, as remote medicine, telemedicine, telemed, telmed, tel-med, or telehealth, is an at least two-way communication between a healthcare provider or providers, such as a physician or a physical therapist, and a patient using audio and/or audiovisual and/or other sensorial or perceptive (e.g., tactile, gustatory, haptic, pressure-sensing-based or electromagnetic (e.g., neurostimulation) communications (e.g., via a computer, a smartphone, or a tablet). Telemedicine may aid a patient in performing various aspects of a rehabilitation regimen for a body part. The patient may use a patient interface in communication with an assistant interface for receiving the remote medical assistance via audio, visual, audiovisual, or other communications described elsewhere herein. Any reference herein to any particular sensorial modality shall be understood to include and to disclose by implication a different one or more sensory modalities.
Telemedicine is an option for healthcare providers to communicate with patients and provide patient care when the patients do not want to or cannot easily go to the healthcare providers' offices. Telemedicine, however, has substantive limitations as the healthcare providers cannot conduct physical examinations of the patients. Rather, the healthcare providers must rely on verbal communication and/or limited remote observation of the patients.
In general, the present disclosure provides systems and methods for a remotely-enabled identification of a user infection. As used herein, “identification” means both a correct identification of a user infection as well as a medically appropriate, normal-standard-of-care attempt to identify or diagnose the user infection, even if the identification is ultimately incorrect or subject to further refinement or modification by a medical professional.
An aspect of the disclosed embodiments includes a system for identifying characteristics associated with a user infection. The system includes a memory device for storing instructions and a processing device communicatively coupled to the memory device. The processing device is configured to execute the instructions to receive, from one or more sensors, one or more sensor inputs pertaining to a potential infected site or anatomical structure; and to generate, by the processing device, an infection probability associated with the infected site, wherein the infection probability is based on the one or more sensor inputs. Another aspect of the disclosed embodiments includes a system for identifying a condition of a user, such as a user having an infection. The system includes a treatment apparatus configured to be manipulated by the user to perform an exercise, such a peddling a bike-like apparatus. An interface is communicably coupled to the treatment apparatus. One or more sensors are configured to sense one or more characteristics of an anatomical structure of the user. As used herein, an anatomical structure may refer to a structure that is anatomical or to a system that is physiological or to any combination thereof. A processing device and a memory are communicatively coupled to the processing device. The memory includes computer readable instructions that, when executed by the processing device, cause the processing device to: receive, from the sensors, one or more sensor inputs representative of the one or more of characteristics of the anatomical structure; calculate an infection probability of a disease based on the one or more characteristics of the anatomical structure; and output, to the interface, a representation of the infection probability.
Another aspect of the disclosed embodiments includes a system for identifying a condition of a user. A treatment apparatus is configured to be manipulated by the user to perform an exercise, such as peddling a bike-like apparatus. One or more sensors are configured to sense one or more characteristics of an anatomical structure of the user. A processing device and a memory are communicatively coupled to the processing device. The memory includes computer readable instructions that, when executed by the processing device, cause the processing device to: receive, from the sensors, one or more sensor inputs representative of the one or more of characteristics of the anatomical structure; generate, from the one or more characteristics, a baseline characteristic and a disease characteristic; generate an infection probability of a disease, where the probability is based on the one or more characteristics, the baseline characteristic and the disease characteristic.
Another aspect of the disclosed embodiments includes a method for identifying a condition. The method includes a step of receiving, from one or more sensors, one or more sensor inputs representative of one or more of characteristics of the anatomical structure. The method includes the step of calculating an infection probability of a disease based on the one or more characteristics of the anatomical structure. The method also includes the step of outputting, to an interface, a representation of the infection probability.
For a more complete understanding of this disclosure and its advantages, reference is now made to the following description, taken in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity.
Various terms are used to refer to particular system components. Different companies may refer to a component by different names—this document does not intend to distinguish between components that differ in name but not function. In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . .” Also, the term “couple” or “couples” is intended to mean either an indirect or direct connection. Thus, if a first device couples to a second device, that connection may be through a direct connection or through an indirect connection via other devices and connections.
The terminology used herein is for the purpose of describing particular example embodiments only, and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” may be intended to include the plural forms as well, unless the context clearly indicates otherwise. The method steps, processes, and operations described herein are not to be construed as necessarily requiring their performance in the particular order discussed or illustrated, unless specifically identified as an order of performance. It is also to be understood that additional or alternative steps may be employed.
The terms first, second, third, etc. may be used herein to describe various elements, components, regions, layers and/or sections; however, these elements, components, regions, layers and/or sections should not be limited by these terms. These terms may be only used to distinguish one element, component, region, layer, or section from another region, layer, or section. Terms such as “first,” “second,” and other numerical terms, when used herein, do not imply a sequence or order unless clearly indicated by the context. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the example embodiments. The phrase “at least one of,” when used with a list of items, means that different combinations of one or more of the listed items may be used, and only one item in the list may be needed. For example, “at least one of: A, B, and C” includes any of the following combinations: A, B, C, A and B, A and C, B and C, and A and B and C. In another example, the phrase “one or more” when used with a list of items means there may be one item or any suitable number of items exceeding one.
In relation to electrical devices (whether standalone or as part of an integrated circuit), the terms “input” and “output” refer to electrical connections to the electrical devices, and shall not be read as verbs requiring action. For example, a differential amplifier (such as an operational amplifier) may have a first differential input and a second differential input, and these “inputs” define electrical connections to the operational amplifier, and shall not be read to require inputting signals to the operational amplifier.
“Assert” shall mean changing the state of a Boolean signal. Boolean signals may be asserted high or with a higher voltage, and Boolean signals may be asserted low or with a lower voltage, at the discretion of the circuit designer. Similarly, “de-assert” shall mean changing the state of the Boolean signal to a voltage level opposite the asserted state.
A processor can include various devices, including a controller. A “controller” shall mean, alone or in combination, individual circuit components, an application specific integrated circuit (ASIC), a microcontroller with controlling software, a digital signal processor (DSP), a processor with controlling software, or a field programmable gate array (FPGA), configured to read inputs and drive outputs responsive to the inputs.
Spatially relative terms, such as “inner,” “outer,” “beneath,” “below,” “lower,” “above,” “upper,” “top,” “bottom,” “inside,” “outside,” “contained within,” “superimposing upon,” and the like, may be used herein. These spatially relative terms can be used for ease of description to describe one element's or feature's relationship to another element(s) or feature(s) as illustrated in the figures. The spatially relative terms may also be intended to encompass different orientations of the device in use, or operation, in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below” or “beneath” other elements or features would then be oriented “above” the other elements or features. Thus, the example term “below” can encompass both an orientation of above and below. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptions used herein interpreted accordingly.
A “treatment plan” may include one or more treatment protocols, and each treatment protocol includes one or more treatment sessions. Each treatment session includes several session periods, with each session period including a particular exercise for treating the body part of the user. For example, a treatment plan for post-operative rehabilitation after a knee surgery may include an initial treatment protocol with twice daily stretching sessions for the first 3 days after surgery and a more intensive treatment protocol with active exercise sessions performed 4 times per day starting 4 days after surgery. A treatment plan may also include information pertaining to a medical procedure to perform on the user, a treatment protocol for the user using a treatment apparatus, a diet regimen for the user, a medication regimen for the user, a sleep regimen for the user, additional regimens, or some combination thereof.
An “infection probability” may include a likelihood of an infection as detected by a system or method described herein. For example, the infection probability may include a scale ranging from 0 (indicating a statistical certainty of no user infection) to 10 (indicating a statistical certainty of a user infection), with the infection probability increasing from 0 to 10. Alternatively, the infection probability may include a scale ranging from 0% (indicating a statistical certainty of no user infection) to 100% (indicating a statistical certainty of a user infection), with the infection probability increasing from 0% to 100%.
A “medical professional” may refer to a doctor, a physician, a physician's assistant, a physical therapist, a nurse (including a registered nurse or a nurse practitioner), a chiropractor, a dentist, acupuncturist, naturopath, physical trainer, coach, personal trainer, or the like. Alternatively, or in combination, a “medical professional” may refer to any person with a credential, license, degree, or the like in the field of medicine, physical therapy, rehabilitation, or the like.
A “healthcare administrator” may include a professional who coordinates with a medical professional, oversees administrative operations, or the like.
A “user” may include a person(s), patient(s), individual(s) using or interacting with a treatment apparatus, a medical professional, and/or a healthcare administrator.
The terms telemedicine, telehealth, telemed, teletherapeutic, etc. may be used interchangeably herein.
The terms “user infection” and “disease” may be used interchangeably herein and in the claim, and include secondary or refractory infections, malfunction, neoplasm, inability to function (e.g., removal, destruction by, e.g., a bullet or accident), attenuation of ability to function or of the integrity or the structure, and the like.
The following discussion is directed to various embodiments of the invention. Although one or more of these embodiments may be preferred, the embodiments disclosed should not be interpreted, or otherwise used, as limiting the scope of the disclosure, including the claims. In addition, one skilled in the art will understand that the following description has broad application, and the discussion of any embodiment is meant only to be exemplary of that embodiment, and not intended to intimate that the scope of the disclosure, including the claims, is limited to that embodiment.
When a user undergoes an invasive procedure (e.g., surgery) or otherwise experiences a breach of the patient's skin, the user can become infected with bacteria, such as at the location of the breach. Typically, the user will either self-diagnose or seek a consultation from a medical professionals. The consultation by the medical professionals generally requires an in-person, face-to-face, pre-arranged appointment with the user, where the medical professionals views a potential infection site of the user to assess whether the potential infection site is an infection. During a telehealth appointment, the medical professional may be able to remotely view the potential infection site of the user to determine a likelihood of the potential infection site being an actual infection (e.g., an infection probability). Depending on the infection probability of the user, an in-person appointment may or may not be necessary.
Determining an infection probability of a user and diagnosing a use infection may be a technically challenging problem. For example, when determining an infection probability, a multitude of information is considered, such as event information, temperature information, pressure information, discoloration information, image information, measurement information, pain information, pain level information, nerve problem information, any other desired information, or a combination thereof. The temperature information may include user temperature, and a subsequent comparison between the user temperature and a normal human temperature range (i.e., a temperature range for a healthy user or temperature below a threshold temperature). Alternatively, or in combination, the temperature information may include a comparison of the user temperature at a potential infected site and the user temperature at a corresponding non-infected site (e.g., the temperature of a potentially infected left knee of the user versus the temperature of a non-infected right knee of a user). Alternatively, or in combination, the temperature information may include a comparison of the user temperature and historical temperature data of other users (e.g., a temperature of a potential infected site of a user who underwent a surgical procedure versus a temperature, including, but not limited to, an average temperature of prior users who underwent the same surgical procedure as the user). The pressure information may include swelling (e.g., perceived swelling or an indication of swelling) of a potential infected site of a user. The discoloration information may include a change in color (e.g., redness or any abnormal color) of the user's skin at the potential infected site. Alternatively, or in combination, the discoloration information may include a comparison between a color of skin at the potential infected site and a color of skin at a corresponding non-infected site (e.g., the color of a potentially infected left knee of the user versus the color of a non-infected right knee of the user). The image information may include a still image or motion imagery (e.g., a video). As an example, the image information may include a comparison between an image of a user's body part before a surgical procedure and an image of the user's body part after the surgical procedure was conducted on the user's body part. The measurement information may include a size measurement of a potential infected site. For example, the measurement information may include sizing a two-dimensional area resulting from a skin breach. As another example, the measurement information may include a dimension, such as a length, of an incision from the event information. The event information may include etiological information, such as information pertaining to an invasive operation event (e.g., a surgical procedure) to a user or to an injury event (e.g., an accident, an intentional cut) to the user. In either event, the etiological information can be at least partially caused by a break, a cut, an opening, an open wound, or another form of a breach to the user's skin. The pain information may include, without limitation, information pertaining to the location or locus of pain experienced by the user, a change in the expressed or perceived level of that pain based on anatomical movements, tense or untensing of muscles, limb extensions or curls and the like. The pain level information may include, without limitation, information pertaining to the user's perceived experience of the intensity of any pain experienced with respect to pain information. Nerve problem information may include, without limitation, user experiences of tingling or neuropathies, of sharp or other types of nerve pain which appear to be neurological or neuromuscular in origin, of conduction issues related to the transmission of electrical impulses rendering an area especially tender, insensate or any level in between and of pain referred to other parts of the user's body.
Another challenge in determining infection probability and infection diagnosis is the collection of user information, or information provided by a user pertaining to the potential infected site. As non-limiting examples, user information may include an indication of a pressure, an indication of a pain level, an indication of a discoloration, and an indication of a mobility. User information may further include any of the information included in determining an infection probability, as set forth in [0033] hereinabove.
Further, another technical problem includes distally diagnosing, via a computing device, or interface (interchangeable with “computing device”), during a telemedicine or telehealth session, a user from a location different from a location at which the user is located. An additional technical problem may involve controlling or enabling the control of, from the different location, a treatment apparatus used by the user at the location at which the user is located. Oftentimes, when a user undergoes rehabilitative surgery (e.g., knee surgery), a medical professional may prescribe a treatment apparatus for the user to use to perform a treatment protocol at their residence or at any mobile location or temporary domicile.
Since a medical professional may be located in a location different from that of the user and the treatment apparatus, it may be technically challenging for the medical professional to monitor the user's actual progress (as opposed to relying on the user's word about their progress) using the treatment apparatus, modify the treatment plan according to the user's progress, adapt the treatment apparatus to the personal characteristics of the user as the user performs the treatment plan, and the like.
Each characteristic of the user, each result of a treatment plan, and each instantiation, modification or cancellation of a parameter, setting, configuration, etc. of the treatment apparatus may be timestamped and correlated with a particular step in the treatment plan. Such a technique may enable determining which steps in the treatment plan lead to desired results (e.g., improved muscle strength, range of motion, etc.) and which steps lead to diminishing returns (e.g., if continuing to exercise after 3 minutes actually delayed or harmed recovery).
Data may be collected from the treatment apparatuses and/or any suitable computing device (e.g., computing devices where personal information is entered, such as a clinician interface or user interface) over time as the user s use the system to perform the various treatment plans. The data that may be collected may include the characteristics of the users, the treatment plans performed by the user s, and the results of the treatment plans.
Embodiments of the present disclosure pertain to a system used to identify characteristics associated with a user infection. For example, the characteristics may include information received from a sensor (or sensors) and/or the user (including one or more user inputs). Additionally, the characteristics may include etiological information provided to the system by a computing system (e.g., a mobile device, a tablet device, a laptop computing device, a desktop computing device) with a user interface (e.g., a display) running a software application, or app, on the user interface. Using at least one of these characteristics, the system can generate an infection probability and/or diagnose a user infection. The diagnosis (of the user infection) may include, for example, a recommendation to apply a medication (e.g., an antibiotic such as penicillin, an antifungal, an antiviral, an anti-inflammatory, an ointment, some other infection-fighting substance, or some other health-improving or healing-promotion substance) to the infected site or, in alternative embodiments, through intramuscular (“IM”), intravenous (“IV”), sublingual, oral or other means of administration.
In some embodiments, the infection probability may be transmitted to various recipients, including the user, the medical professional, an insurance provider, a healthcare administrator, a power of attorney, and/or other third party. The transmission may include displaying an image on an interface, or otherwise communicating with a user through an interface. When the recipient is the user or the user's family or caregivers, the user or the user's family or caregivers can contact the medical professional, the insurance provider, the healthcare administrator, the power of attorney, and/or other third party to set up an appointment, such as a telemedicine-enabled appointment, and thereupon receive a treatment plan. When the recipient is one of the medical professional, the insurance provider, and the healthcare administrator, the recipient can contact the user and set up the appointment with the user to discuss the user's health condition and a treatment plan.
In some embodiments, the system can receive or generate a threshold infection probability. When the infection probability is at least at (i.e., at or above) the threshold infection probability, the system may determine that a recommended treatment plan is necessary. As a result, the recommendation can be transmitted with the infection probability. The recommendation may include at least one of a treatment plan for the user and a telemedicine-enabled appointment with the user to discuss to discuss a treatment plan. The recipient(s) of the recommendation may include any recipient, as set forth in [0039] hereinabove.
Some embodiments of the present disclosure pertain to diagnosing a user infection. For example, a system can use the information to identify a type of an infection incurred by the user. In some embodiments, a system can use information from the sensor(s) and/or the user to diagnose a potential infected site of the user. Additionally, the system may use event information, including etiological information, to diagnose the user infection. The diagnosed infection can be transmitted to a recipient, which may include any recipient, as set forth in [0039] hereinabove. The recipient can schedule a telemedicine-enabled appointment to discuss the infection diagnosis and a recommended treatment plan.
Some embodiments of the present disclosure pertain to using an artificial intelligence engine and/or machine learning engine to dynamically update the treatment plan based on sensor input information and/or user input information received by the system. For example, a user may undergo a treatment for a user infection. Subsequently, one or more characteristics pertaining to the user may be collected during or after the user performs the treatment plan. For example, temperature information, pressure information, discoloration information, image information, and measurement information may be collected from, for example, the potential infection site during or after the user performs the treatment plan. The artificial intelligence engine and/or machine learning engine can use the characteristics to determine whether the user infection is decreasing (i.e., the user is improving and/or the user infection is healing) or increasing (i.e., the user is not improving and/or the user infection is not healing or worsening) and thereupon modify the treatment plan for improved results.
The artificial intelligence engine and/or a machine learning engine may generate a modified treatment plan, which provides an updated treatment regimen for the user. For example, for an infection probability that is either increasing (relative to a previously generated infection probability) and/or equal to or exceeding a threshold infection, the modified treatment plan can generate one or more of a recommendation that includes additional and/or modified treatments (e.g., additional/modified medication, additional/modified recovery steps), a recommendation to set up a telemedicine-enabled appointment to discuss additional/modified treatments, or the like. Conversely, for an infection probability that is either decreasing (relative to a previously generated infection probability) or below a threshold infection, the modified treatment plan can recommend a modification to the treatments, such as a reduction/modification of medication, a reduction/modification of recovery procedures, a recommendation to set up a telemedicine-enabled appointment to discuss fewer/modified treatments, or the like.
In some embodiments, when a telemedicine-enabled appointment is recommended, the telemedicine-enabled appointment is automatically scheduled between a user or the user's family or caregivers and one or more of a medical professional, an insurance provider, and a healthcare administrator. For example, a system, an artificial intelligence engine, or a machine learning engine with calendar access privileges of the patient or the user's family or caregivers and the medical professional can review the respective calendars of the user or the user's family or caregivers and the medical professional, and populate (e.g., fill in) the telemedicine-enabled appointment into the respective calendars.
The system 10 also includes a server 30 configured to store and to provide data related to managing the treatment plan. The server 30 may include one or more computers and may take the form of a distributed and/or virtualized computer or computers. The server 30 may also include a first communication interface 32 configured to communicate with the clinician interface 20 via a first network 34. In some embodiments, the first network 34 may include wired and/or wireless network connections such as Wi-Fi, Bluetooth, ZigBee, Near-Field Communications (NFC), cellular data networks, etc. The server 30 may include a first processor 36 and a first machine-readable storage memory 38, which may be called a “memory” for short, holding first instructions 40 for performing the various actions of the server 30 for execution by the first processor 36. The server 30 is configured to store data regarding the treatment plan. For example, the memory 38 includes a system data store 42 configured to hold system data, such as data pertaining to treatment plans for treating one or more users. The server 30 is also configured to store data regarding performance by a user in following a treatment plan. For example, the memory 38 includes a user data store 44 configured to hold user data, such as data pertaining to the one or more users, including data representing each user's performance within the treatment plan.
In some embodiments, the server 30 may execute an artificial intelligence (AI) engine 11 that uses one or more machine learning models 13 to perform at least one of the embodiments disclosed herein. The server 30 may include a training engine 9 capable of generating the one or more machine learning models 13. Using one or more inputs (e.g., inputs from one or more sensors, inputs from a user) real-time data, and/or historical data correlations, the one or more machine learning models 13 may be trained to select treatment plans for user s, determine infection probabilities of user s, diagnose user infections, modify treatment plans for users, and control a treatment apparatus 70, among other things. The one or more machine learning models 13 may be generated by the training engine 9 and may be implemented in computer instructions executable by one or more processing devices of the training engine 9 and/or the server 30. To generate the one or more machine learning models 13, the training engine 9 may train the one or more machine learning models 13. The one or more machine learning models 13 may be used by the artificial intelligence engine 11.
The training engine 9 may be a rackmount server, a router computer, a personal computer, a portable digital assistant, a smartphone, a laptop computer, a tablet computer, a netbook, a desktop computer, an Internet of Things (IoT) device, any other desired computing device, or any combination of the above. The training engine 9 may be cloud-based or a real-time software platform, and it may include privacy software or protocols, and/or security software or protocols.
To train the one or more machine learning models 13, the training engine 9 may use a training data set of a corpus of the characteristics of multiple types of infections users can contract, the details (e.g., treatment protocol including the type of medications, amounts of each medication to apply to or use on or in the user, how often to treat the infection with medication, a schedule of exercises and rest periods, infection probability, wound size, parameters/configurations/settings of the treatment apparatus 70 throughout each step of the treatment plan, etc.) of the treatment plans performed by the users using the treatment apparatus 70, and the results of the treatment plans performed by the people. The one or more machine learning models 13 may be trained to match patterns of characteristics of a user with characteristics of other people in assigned to a particular cohort. The term “match” may refer to an exact match, a correlative match, a substantial match, etc. The one or more machine learning models 13 may be trained to receive the characteristics of a user as input, map the characteristics to characteristics of people assigned to a cohort, and select a treatment plan from that cohort. The one or more machine learning models 13 may also be trained to control, based on the treatment plan, the machine learning apparatus 70.
Different machine learning models 13 may be trained to recommend different treatment plans for different desired results. For example, one of the one or more machine learning models 13 may be trained to recommend treatment plans for most effective recovery, while another of the one or more machine learning models 13 may be trained to recommend treatment plans based on, for example, speed of recovery, cost of recovery, strength resulting from recovery, etc.
Using training data that includes training inputs and corresponding target outputs, the one or more machine learning models 13 may refer to model artifacts created by the training engine 9. The training engine 9 may find patterns in the training data wherein such patterns map the training input to the target output, and generate the machine learning models 13 that capture these patterns. In some embodiments, the artificial intelligence engine 11, the database 33, and/or the training engine 9 may reside on another component (e.g., assistant interface 94, clinician interface 20, etc.) depicted in
The one or more machine learning models 13 may include, e.g., a single level of linear or non-linear operations (e.g., a support vector machine [SVM]) or the machine learning models 13 may be a deep network, i.e., a machine learning model including multiple levels of non-linear operations. Examples of deep networks are neural networks including generative adversarial networks, convolutional neural networks, recurrent neural networks with one or more hidden layers, and fully connected neural networks (e.g., each neuron may transmit its output signal to the input of the remaining neurons, as well as to itself). For example, the machine learning model may include numerous layers and/or hidden layers that perform calculations (e.g., dot products) using various neurons.
The system 10 also includes a user interface 50 configured to communicate information to a user and to receive feedback from the user. Specifically, the user interface includes an input device 52 and an output device 54, which may be collectively called a user interface 52, 54. The input device 52 may include one or more devices, such as a keyboard, a mouse, a touchscreen input, a gesture sensor (including sensors for eye blinking used to communicate), a haptic device, and/or a microphone and processor configured for voice recognition. The output device 54 may take one or more different forms including, for example, a computer monitor or display screen on a tablet, smartphone, or a smartwatch. The output device 54 may include other hardware and/or software components such as a projector, virtual reality capability, augmented reality capability, etc. The output device 54 may incorporate various different visual, audio, or other sensorial or presentation technologies. For example, the output device 54 may include a non-visual display, such as an audio signal, which may include spoken language and/or other sounds such as tones, chimes, and/or melodies, which may signal different conditions and/or directions. The output device 54 may include one or more different display screens presenting various data and/or interfaces or controls for use by the user. The output device 54 may include graphics, which may be presented by a web-based interface and/or by a computer program or application (“app”).
As shown in
The user interface 50 includes a second processor 60 and a second machine-readable storage memory 62 holding second instructions 64 for execution by the second processor 60 for performing various actions of user interface 50. The second machine-readable storage memory 62 also includes a local data store 66 configured to hold data, such as data pertaining to a treatment plan and/or user data, such as data representing a user's performance within a treatment plan. The user interface 50 also includes a local communication interface 68 configured to communicate with various devices for use by the user in the vicinity of the user interface 50. The local communication interface 68 may include wired and/or wireless communications. In some embodiments, the local communication interface 68 may include a local wireless network such as Wi-Fi, Bluetooth, ZigBee, Near-Field Communications (NFC), cellular data networks, etc.
The system 10 also includes a treatment apparatus 70 configured to be manipulated by the user and/or to manipulate a body part of the user for performing activities according to the treatment plan. In some embodiments, the treatment apparatus 70 may take the form of an exercise and rehabilitation apparatus configured to perform and/or to aid in the performance of a rehabilitation regimen, which may be or include an orthopedic rehabilitation regimen, and the treatment includes rehabilitation of a body part of the user, such as a joint and/or a bone and/or a tendon and/or a ligament and/or a muscle group. The treatment apparatus 70 may be any suitable medical, rehabilitative, therapeutic, etc. apparatus configured to be controlled distally via another computing device to treat a user and/or exercise the user, and such exercise or treatment may also include taking and analyzing and/or storing measurements of neurological or neuromuscular aspects of the user or the user's performance as well as of vital signs of the user. The treatment apparatus 70 may be an electromechanical machine including one or more weights, an electromechanical bicycle, an electromechanical spin-wheel, a smart-mirror, a treadmill, or the like. The body part may include, for example, a spine, a hand, a foot, a knee, or a shoulder. The body part may include a part of a joint, a bone, or a muscle group, such as one or more vertebrae, a tendon, or a ligament. As shown in
The internal sensors 76 may measure one or more operating characteristics of the treatment apparatus 70 such as, for example, a force, a position, a speed, and/or a velocity. In some embodiments, the internal sensors 76 may include a position sensor configured to measure at least one of a linear motion or an angular motion of a body part of the user. For example, an internal sensor 76 in the form of a position sensor may measure a distance that (or a time in which) the user is able to move a part of the treatment apparatus 70, where such distance (or time) may correspond to a range of motion that the user's body part is able to achieve. In some embodiments, the internal sensors 76 may include a force sensor configured to measure a force applied by the user. For example, an internal sensor 76 in the form of a force sensor may measure a force or weight the user is able to apply, using a particular body part, to the treatment apparatus 70.
The system 10 shown in
The system 10 shown in
The system 10 shown in
The system 10 shown in
The system 10 shown in
The system 10 includes an assistant interface 94 for an assistant, such as a doctor, a nurse, a physical therapist, or a technician, to remotely communicate with the user interface 50 and/or the treatment apparatus 70. Such remote communications may enable the assistant to provide assistance or guidance to a user using the system 10. More specifically, the assistant interface 94 is configured to communicate a telemedicine signal 96, 97, 98a, 98b, 99a, 99b with the user interface 50 via a network connection such as, for example, via the first network 34 and/or the second network 58. The telemedicine signal 96, 97, 98a, 98b, 99a, 99b includes one of an audio signal 96, an audiovisual signal 97, an interface control signal 98a for controlling a function of the user interface 50, an interface monitor signal 98b for monitoring a status of the user interface 50, an apparatus control signal 99a for changing an operating parameter of the treatment apparatus 70, and/or an apparatus monitor signal 99b for monitoring a status of the treatment apparatus 70. In some embodiments, each of the control signals 98a, 99a may be unidirectional, conveying commands from the assistant interface 94 to the user interface 50. In some embodiments, in response to successfully receiving a control signal 98a, 99a and/or to communicate successful and/or unsuccessful implementation of the requested control action, an acknowledgement message may be sent from the user interface 50 to the assistant interface 94. In some embodiments, each of the monitor signals 98b, 99b may be unidirectional, status-information commands from the user interface 50 to the assistant interface 94. In some embodiments, an acknowledgement message may be sent from the assistant interface 94 to the user interface 50 in response to successfully receiving one of the monitor signals 98b, 99b.
In some embodiments, the user interface 50 may be configured as a pass-through for the apparatus control signals 99a and the apparatus monitor signals 99b between the treatment apparatus 70 and one or more other devices, such as the assistant interface 94 and/or the server 30. For example, the user interface 50 may be configured to transmit an apparatus control signal 99a in response to an apparatus control signal 99a within the telemedicine signal 96, 97, 98a, 98b, 99a, 99b from the assistant interface 94.
In some embodiments, the assistant interface 94 may be presented on a shared physical device as the clinician interface 20. For example, the clinician interface 20 may include one or more screens that implement the assistant interface 94. Alternatively or additionally, the clinician interface 20 may include additional hardware components, such as a video camera, a speaker, and/or a microphone, to implement aspects of the assistant interface 94.
In some embodiments, one or more portions of the telemedicine signal 96, 97, 98a, 98b, 99a, 99b may be generated from a prerecorded source (e.g., an audio recording, a video recording, or an animation) for presentation by the output device 54 of the user interface 50. For example, a tutorial video may be streamed from the server 30 and presented upon the user interface 50. Content from the prerecorded source may be requested by the user via the patient interface 50. Alternatively, via a control on the assistant interface 94, the assistant may cause content from the prerecorded source to be played on the user interface 50.
The assistant interface 94 includes an assistant input device 22 and an assistant display 24, which may be collectively called an assistant user interface 22, 24. The assistant input device 22 may include one or more of a telephone, a keyboard, a mouse, a trackpad, or a touch screen, for example. Alternatively or additionally, the assistant input device 22 may include one or more microphones. In some embodiments, the one or more microphones may take the form of a telephone handset, headset, or wide-area microphone or microphones configured for the assistant to speak to a user via the user interface 50. In some embodiments, assistant input device 22 may be configured to provide voice-based functionalities, with hardware and/or software configured to interpret spoken instructions by the assistant by using the one or more microphones. The assistant input device 22 may include functionality provided by or similar to existing voice-based assistants such as Siri by Apple, Alexa by Amazon, Google Assistant, or Bixby by Samsung. The assistant input device 22 may include other hardware and/or software components. The assistant input device 22 may include one or more general purpose devices and/or special-purpose devices.
The assistant display 24 may take one or more different forms including, for example, a computer monitor or display screen on a tablet, a smartphone, or a smart watch. The assistant display 24 may include other hardware and/or software components such as projectors, virtual reality capabilities, or augmented reality capabilities, etc. The assistant display 24 may incorporate various different visual, audio, or other presentation technologies. For example, the assistant display 24 may include a non-visual display, such as an audio signal, which may include spoken language and/or other sounds such as tones, chimes, melodies, and/or compositions, which may signal different conditions and/or directions. The assistant display 24 may include one or more different display screens presenting various data and/or interfaces or controls for use by the assistant. The assistant display 24 may include graphics, which may be presented by a web-based interface and/or by a computer program or application.
In some embodiments, the system 10 may provide computer translation of language from the assistant interface 94 to the user interface 50 and/or vice-versa. The computer translation of language may include computer translation of spoken language and/or computer translation of text. Additionally or alternatively, the system 10 may provide voice recognition and/or spoken pronunciation of text. For example, the system 10 may convert spoken words to printed text and/or the system 10 may audibly speak language from printed text. The system 10 may be configured to recognize spoken words by any or all of the user, the clinician, and/or the assistant. In some embodiments, the system 10 may be configured to recognize and react to spoken requests or commands by the user. For example, the system 10 may automatically initiate a telemedicine session in response to a verbal command by the user (which may be given in any one of several different languages).
In some embodiments, the server 30 may generate aspects of the assistant display 24 for presentation by the assistant interface 94. For example, the server 30 may include a web server configured to generate the display screens for presentation upon the assistant display 24. For example, the artificial intelligence engine 11 may generate recommended treatment plans and/or excluded treatment plans for users and generate the display screens including those recommended treatment plans and/or external treatment plans for presentation on the assistant display 24 of the assistant interface 94. In some embodiments, the assistant display 24 may be configured to present a virtualized desktop hosted by the server 30. In some embodiments, the server 30 may be configured to communicate with the assistant interface 94 via the first network 34. In some embodiments, the first network 34 may include a local area network (LAN), such as an Ethernet network. In some embodiments, the first network 34 may include the Internet, and communications between the server 30 and the assistant interface 94 may be secured via privacy enhancing technologies, such as, for example, by using encryption over a virtual private network (VPN). Alternatively or additionally, the server 30 may be configured to communicate with the assistant interface 94 via one or more networks independent of the first network 34 and/or other communication means, such as a direct wired or wireless communication channel. In some embodiments, the user interface 50 and the treatment apparatus 70 may each operate from a user location geographically separate from a location of the assistant interface 94. For example, the user interface 50 and the treatment apparatus 70 may be used as part of an in-home rehabilitation system, which may be aided remotely by using the assistant interface 94 at a centralized location, such as a clinic or a call center.
In some embodiments, the assistant interface 94 may be one of several different terminals (e.g., computing devices) that may be grouped together, for example, in one or more call centers or at one or more clinicians' offices. In some embodiments, a plurality of assistant interfaces 94 may be distributed geographically. In some embodiments, a person (e.g., medical professional) may work as an assistant remotely from any conventional office infrastructure. Such remote work may be performed, for example, where the assistant interface 94 takes the form of a computer and/or telephone. This remote work functionality may allow for work-from-home arrangements that may include part time and/or flexible work hours for an assistant.
Specifically, the overview display 120 includes a user profile display 130 presenting biographical information regarding a user using the treatment apparatus 70. The user profile display 130 may take the form of a portion or region of the overview display 120, as shown in
In some embodiments, the user profile display 130 may present information regarding the treatment plan for the user to follow in using the treatment apparatus 70. Such treatment plan information may be limited to an assistant who is a medical professional, such as a doctor or physical therapist. For example, a medical professional assisting the user with an issue regarding the treatment regimen may be provided with treatment plan information, whereas a technician troubleshooting an issue with the treatment apparatus 70 may not be provided with any information regarding the user's treatment plan.
In some embodiments, one or more recommended treatment plans and/or excluded treatment plans may be presented in the user profile display 130 to the assistant. The one or more recommended treatment plans and/or excluded treatment plans may be generated by the artificial intelligence engine 11 of the server 30 and received from the server 30 in real-time during, inter alia, a telemedicine or telehealth session.
The example overview display 120 shown in
User access controls may be used to limit access, including what data is available to be viewed and/or modified, on any or all of the user interfaces 20, 50, 90, 92, 94 of the system 10. In some embodiments, user access controls may be employed to control what information is available to any given person using the system 10. For example, data presented on the assistant interface 94 may be controlled by user access controls, with permissions set depending on the assistant/user's need for and/or qualifications to view that information.
The example overview display 120 shown in
The example overview display 120 shown in
In some embodiments, the user interface setting control 154 may include collaborative browsing or co-browsing capability for the assistant to remotely view and/or control the user interface 50. For example, the user interface setting control 154 may enable the assistant to remotely enter text to one or more text entry fields on the user interface 50 and/or to remotely control a cursor on the user interface 50 using a mouse or touchscreen of the assistant interface 94.
In some embodiments, using the user interface 50, the user interface setting control 154 may allow the assistant to change a setting that cannot be changed by the user. For example, the user interface 50 may be precluded from accessing a language setting to prevent a user from inadvertently switching, on the user interface 50, the language used for the displays, whereas the user interface setting control 154 may enable the assistant to change the language setting of the user interface 50. In another example, the user interface 50 may not be able to change a font size setting to a smaller size in order to prevent a user from inadvertently switching the font size used for the displays on the user interface 50 such that the display would become illegible to the user, whereas the user interface setting control 154 may provide for the assistant to change the font size setting of the user interface 50.
The example overview display 120 shown in
The example overview display 120 shown in
The apparatus control 160 may include an apparatus setting control 164 for the assistant to adjust or control one or more aspects of the treatment apparatus 70. The apparatus setting control 164 may cause the assistant interface 94 to generate and/or to transmit an apparatus control signal 99 for changing an operating parameter of the treatment apparatus 70, (e.g., a pedal radius setting, a resistance setting, a target RPM, etc.). The apparatus setting control 164 may include a mode button 166 and a position control 168, which may be used in conjunction for the assistant to place an actuator 78 of the treatment apparatus 70 in a manual mode, after which a setting, such as a position or a speed of the actuator 78, can be changed using the position control 168. The mode button 166 may provide for a setting, such as a position, to be toggled between automatic and manual modes. In some embodiments, one or more settings may be adjustable at any time, and without having an associated auto/manual mode. In some embodiments, the assistant may change an operating parameter of the treatment apparatus 70, such as a pedal radius setting, while the user is actively using the treatment apparatus 70. Such “on the fly” adjustment may or may not be available to the user using the user interface 50. In some embodiments, the apparatus setting control 164 may allow the assistant to change a setting that cannot be changed by the user using the user interface 50. For example, the user interface 50 may be precluded from changing a preconfigured setting, such as a height or a tilt setting of the treatment apparatus 70, whereas the apparatus setting control 164 may provide for the assistant to change the height or tilt setting of the treatment apparatus 70.
The example overview display 120 shown in
In some embodiments, the audio or an audiovisual communications session with the user interface 50 may take place, at least in part, while the user is performing the rehabilitation regimen upon the body part. The user communications control 170 may take the form of a portion or region of the overview display 120, as shown in
The example overview display 120 shown in
Sensors can be used to monitor the user and provide one or more inputs to the system 10 described in
Also, the sensing device 600a can be used to detect a change (e.g., an increase or a decrease) in temperature of the user's body part, thereby indicating an increase or a decrease in the user's temperature. For example, the sensing device 600a can transmit, at different times, the temperature information to the system 10, and the system 10 can analyze and compare each instance of detected temperature information, and subsequently determine an increased user temperature, a decreased user temperature, or no change in user temperature. The system 10 can use the change in user temperature to determine an infection probability of a potential infected site of the user and/or diagnose the user for an infection.
Also, the sensing device 600b can be used to detect a change (e.g., an increase or a decrease) in swelling of the user's body part, thereby indicating increased swelling or decreased swelling. For example, the sensing device 600b can transmit, at different times, the detected pressure information to the system 10, and the system 10 can analyze and compare one or more instances of the detected pressure information, and subsequently determine an increased swelling, a decreased swelling, or no change in swelling. The system 10 can use the change in swelling to determine an infection probability of a potential infected site of the user and/or diagnose the user for an infection.
Also, the sensing device 600c can be used to detect a change (e.g., an increase in a measurement or a decrease in a measurement) in the dimensional information of the breach. For example, the sensing device 600b can transmit, at different times, the dimensional information to the system 10, and the system 10 can analyze and compare one or more instances of the dimensional information, and subsequently determine an increased dimensional information, a decreased dimensional information, or no change in dimensional information. The system 10 can use the change in dimensional information to determine an infection probability of a potential infected site of the user and/or diagnose the user for an infection.
In addition to dimensional information, the data collected by the sensing device 600c can be analyzed for different purposes. For example, the sensing device 600c can capture images (e.g., motion/video images), and analyze the images to determine user mobility at the potential infected site. The increase in user mobility may be inversely proportional to the infection probability. In other words, the infection probability may increase or decrease with decreasing or increasing, respectively, user mobility at the potential infected site. As another example, the sensing device 600c can capture an image, and analyze the image to determine discoloration (e.g., redness of the skin, or other skin color abnormalities) of the user's skin at the potential infected site. The discoloration be directly proportional to the infection probability. In other words, the infection probability may increase or decrease with a measured amount of increasing or decreasing, respectively, discoloration at the potential infected site. As yet another example, the sensing device 600c can capture an image (e.g., still or motion/video images), and analyze the image to determine the temperature of the user at the potential infected site. Accordingly, in some embodiments, the sensing device 600c includes infrared sensing capabilities or any other desired sensing capabilities.
The system 10 can receive information from one or more of the sensors 600a, 600b, and 600c, and use the information to determine an infection probability of a potential infected site of the user and/or diagnose the user for an infection. Additionally, the system 10 can use information received from one the sensors 600a, 600b, and 600c to modify a treatment plan for the user. For example, the training engine 9 described in
For simplicity of explanation, the method 700 is depicted and described as a series of operations. However, operations in accordance with this disclosure can occur in various orders and/or concurrently, and/or with other operations not presented and described herein. For example, the operations depicted in the method 700 may occur in combination with any other operation of any other method disclosed herein. Furthermore, not all illustrated operations may be required to implement the method 700 in accordance with the disclosed subject matter. In addition, those skilled in the art will understand and appreciate that the method 700 could alternatively be represented as a series of interrelated states via a state diagram or events.
At step 702, the processing device receives, from a sensor, a sensor input pertaining to a potential infected site of a user. The sensor input may include an input, or signal, from a temperature sensor, a pressure sensor, and/or a camera described herein. Accordingly, the sensors shown and described in
In addition to receiving a sensor input (or inputs), the processing device can also receive and use user input information. For example, the user information may include symptoms such as an indication of a pressure, an indication of a pain level, and/or an indication of a mobility. In order to provide the user input information to the processing device, a computing device (e.g., mobile device, desktop computer, laptop computer) with a user interface (e.g., a display of the computing device) can present a software application, or app.
At step 704, the processing device generates an infection probability associated with the infected site. The infection probability is based at least in part on the sensor input. Alternatively, or in combination, the infection probability is based on the user input information. The infection probability can be presented as a range (e.g., 0-10, 0%-100%), with an increasing value in the range indicating a relatively higher infection probability.
Optionally, at step 706, the infection probability can be transmitted to one or more recipients. For example, the infection probability can be transmitted to the user, a medical professional, an insurance provider, and/or a healthcare administrator. Once received, a telemedicine-enabled appointment can be scheduled between the user and one or more of the medical professional, the insurance provider, and/or the healthcare administrator. The telemedicine-enabled appointment allows the user to remotely receive communication (e.g., the treatment plan) from any of the medical professional, the insurance provider, and/or the healthcare administrator. In other words, by using the telemedicine-enabled appointment, the user is not required to make an in-office visit and does need to be in physical proximity to (i.e., not in the same room or building as) the medical professional, the insurance provider, and/or the healthcare administrator. By transmitting the infection probability during instances when the infection probability is at least at a threshold infection probability, some appointments may be avoided when the infection probability is sufficiently low (i.e., below the threshold infection probability). However, it should be noted that in some embodiments, the infection probability can be transmitted the medical professional, the insurance provider, and/or the healthcare administrator, even when the infection probability is below the threshold infection probability.
In some embodiments, the infection probability is transmitted when the infection probability is at least (i.e., equals or exceeds) at a threshold infection probability. The processing device can receive or identify the threshold infection probability, which may correspond to a particular infection or a risk level of infection that requires a treatment plan. Different risk levels of infection can be assigned to different users based upon one or more factors, including, but not limited to, the user's age, the user's medical history (e.g., an immunocompromised user, a user with little or no prior medical issues), the type of infection identified, and/or the known ability for a medication to effectively treat an infection. Accordingly, the threshold infection probability can vary for each user based upon a variety of factors. Moreover, for the same type of infection, users with a relatively high risk level (e.g., an older user with prior medical issues) may be assigned a relatively lower threshold infection probability, as compared to user s with a relatively high risk level (e.g., a younger user with no prior medical issues). As a result, in some instances, the infection probability is more likely to reach at least the threshold infection probability for user s with a relatively high risk level. In this regard, the method 700 may provide a more efficient method for a medical professional, an insurance provider, and/or a healthcare administrator to interact with user s.
In some embodiments, the processing device receives or identifies multiple the threshold infection probabilities, with each threshold infection probability corresponding to a particular risk level. For example, when the processing device receives or identifies a first threshold infection probability and a second threshold probability, the first threshold infection probability may correspond to a relatively low risk level while the second threshold infection probability may correspond to a relatively high risk level. In this regard, the first threshold infection probability may indicate that the user should seek a treatment plan for the potential infected site, while the second threshold infection probability may indicate that the user should seek immediate treatment for the potential infected site or immediately set up a telemedicine-enabled appointment with a medical professional. Accordingly, the processing device can compare the infection probability with multiple threshold infection probabilities, and provide multiple ways to treat an infection based on the associated risk level.
The processing device can use the characteristics to diagnose the potential infected site. For example, using one or more of the sensor input and the user input information, the processing device may determine a type of infection (e.g., a bacterial infection such as a Staph infection caused by staphylococcus bacteria, a germ, a parasite, a virus, or some combination thereof) associated with the potential infected site. Moreover, based on the diagnosis, the processing device can recommend a treatment plan to the user. The diagnosis and/or the treatment plan can be transmitted to the user. In some embodiments, the diagnosis and/or the treatment plan is first transmitted to the medical professional, the insurance provider, and/or the healthcare administrator for review, and once approved, is transmitted to the user.
Alternatively, or in combination, the processing device can receive and use etiological information associated with the potential infected site to determine an infection probability and/or diagnose an infection. For example, the processing device can receive information indicating that the user has undergone an invasive operation event (e.g., a surgical procedure) at the potential infected site, thereby indicating the type of incision made to the user. In another example, the processing device can receive information indicating that the user has undergone an injury event (e.g., an accident) at the potential infected site, thereby indicating the user has an open wound or a cut.
Additionally, the processing device can receive multiple sensor inputs to determine an infection probability. For example, the processing device can receive a first input at a potential infected site and a second input from a non-infected site. A “non-infection site” may refer to, for example, no statistical probability of infection). The processing device can compare the first input with the second input to generate the infection probability. This may include, for example, a comparison between a first temperature (from the first input) at the potential infected site (e.g., a user's left knee), and a second temperature (from the second input) at the non-infected site (e.g., a user's right knee). In some embodiments, the processing device analyzes the comparison to determine the infection probability. For example, the difference between the first temperature and the second temperature can be directly proportional to the infection probability, and accordingly, the processing device determines a relatively high infection probability for a larger difference (e.g., 3 degrees on a Celsius or Fahrenheit scale) between the first temperature and the second temperature, and conversely, the processing device determines a relatively low infection probability for a smaller difference (e.g., 0.5 degrees on a Celsius or Fahrenheit scale) between the first temperature and the second temperature. Alternatively, or in combination, the processing device can use a predetermined difference between the first temperature and the second temperature to determine the infection probability. For example, in some embodiments, the processing device may require the difference between the first temperature and the second temperature be at least a specified difference (e.g., 2 degrees on a Celsius or Fahrenheit scale), as oppose to the first temperature simply being greater than the second temperature. In this regard, the processing device may determine the infection probability with increased accuracy and/or prevent or limit “false positives” with respect to determine the presence of an infection.
At step 802, the processing device receives, from a sensor, a sensor input pertaining to a potential infected site of a user. The sensor input from the sensor may include an input from a temperature sensor, a pressure sensor, or a camera described herein. Accordingly, the sensor input may include characteristics such as temperature information, pressure information, discoloration information, image information, vital sign information, or measurement information.
At step 804, the processing device receives a user input. The user input information may be provided by the user, either from the user to the processing device via computing system or indirectly via a medical professional, the insurance provider, and/or the healthcare administrator. The user input may include symptoms such as an indication of a pressure, an indication of a pain level, and an indication of a mobility.
At step 806, the processing device identifies, using the sensor input and the user input, the user infection associated with the user. In some embodiments, the sensor input and/or the user input is used to identify the user infection.
Additionally, the processing device can receive and use etiological information associated with the user. For example, the processing device can receive information indicating the user has undergone an invasive operation event (e.g., surgical procedure) at the potential infected site, thereby indicating the type of incision to the user. In another example, the processing device can receive information indicating the user has undergone an injury event (e.g., accident) at the potential infected site, thereby indicating the user has an open wound or a cut.
When the user infection is identified, the processing device can initiate additional steps. For example, the processing device can generate a recommendation for one or more of a medication, a treatment plan, and a visit with a medical professional. In the case of the visit with the medical professional, a telemedicine-enabled appointment can be scheduled between the user and the medical professional.
At step 902, the treatment plan for the user is received. For example, the processing device may receive treatment plan from the user's medical professional. The treatment plan may include one or more recommendations for the user to treat the user infection. For example, the treatment plan may include a medication, and/or a visit with a medical professional. In the case of the visit with the medical professional, a telemedicine-enabled appointment can be scheduled between the user and the medical professional.
At step 904, the processing device receives, from a sensor, a sensor input pertaining to a potential infected site of a user. The sensor input from the sensor may include an input from a temperature sensor, a pressure sensor, or a camera described herein. Accordingly, the sensor input may include characteristics such as temperature information, pressure information, discoloration information, image information, vital sign information, measurement information, any other desired information, or combination thereof.
At step 906, the processing device receives a user input. In some embodiments, the user provides the user input through a computing system (e.g., a mobile device, a tablet device, a laptop computing device, a desktop computing device) with a user interface (e.g., a display) running a software application, or app, on the user interface. In some embodiments, the user provides the user input indirectly via a medical professional, the insurance provider, and/or the healthcare administrator. The user input may include symptoms such as an indication of a pressure, an indication of discoloration, an indication of a pain level, and/or an indication of a mobility.
At step 908, the artificial intelligence engine uses the sensor input and the user input to adjust the treatment plan. For example, a treatment plan may include different types of medications, with each type of medication designed to treat different risk level and/or severities. When the processing device receives a treatment plan that recommends a first medication associated with a relatively low risk level or relatively low severity of a user infection, the artificial intelligence engine may use the sensor input and the user input to adjust the treatment plan and subsequently recommend a second medication associated with a relatively high risk level or relatively high severity of a user infection. Conversely, when the processing device receives a treatment plan that recommends the second medication, the artificial intelligence may adjust the treatment plan, based on the sensor input and the user input, and subsequently recommend the first medication. Accordingly, the artificial intelligence engine can modify the medication based on an increasing or decreasing risk/severity level.
In addition to adjusting the type of medication, the artificial intelligence engine can adjust treatment plans in other ways. For example, a treatment plan may include a recommended frequency of application of a medication, a recommendation to rest or immobilize the user (e.g., at the user infection site), and/or a recommendation to wrap/cover the user infection. The additional ways for adjusting the treatment plan can be modified by the artificial intelligence engine to account for a change in risk level or severity of a user infection. For example, when one or more of the sensor input and the user input provide(s) an indication of a decreased risk level or decreased severity of the patient infection, the artificial intelligence engine may adjust the treatment plan, and subsequently recommend a decreased application frequency of the medication, and/or a reduction in covering/wrapping the user infection. Conversely, when one or more of the sensor input and the user input provide(s) an indication of an increased risk level or increased severity of the user infection, the artificial intelligence engine may adjust the treatment plan, and subsequently recommend an increased application frequency of the medication, a recommendation for the user to rest, and/or a recommendation to cover/wrap the user infection. Accordingly, the artificial intelligence engine can modify the treatment plan, based on an increasing or decreasing risk/severity level, to adapt to real-time characteristics of the user.
The computer system 1000 includes a processing device 1002, a main memory 1004 (e.g., read-only memory (ROM), flash memory, solid state drives (SSDs), dynamic random access memory (DRAM) such as synchronous DRAM (SDRAM), a static memory 1006 (e.g., flash memory, solid state drives (SSDs), static random access memory (SRAM), and a data storage device 1008, which communicate with each other via a bus 1010.
Processing device 1002 represents one or more general-purpose processing devices such as a microprocessor, central processing unit, or the like. More particularly, the processing device 1002 may be a complex instruction set computing (CISC) microprocessor, reduced instruction set computing (RISC) microprocessor, very long instruction word (VLIW) microprocessor, or a processor implementing other instruction sets or processors implementing a combination of instruction sets. The processing device 1402 may also be one or more special-purpose processing devices such as an application specific integrated circuit (ASIC), a system on a chip, a field programmable gate array (FPGA), a digital signal processor (DSP), network processor, or the like. The processing device 1402 is configured to execute instructions for performing any of the operations and steps discussed herein.
The computer system 1000 may further include a network interface device 1012. The computer system 1000 also may include a video display 1014 (e.g., a liquid crystal display (LCD), a light-emitting diode (LED), an organic light-emitting diode (OLED), a quantum LED, a cathode ray tube (CRT), a shadow mask CRT, an aperture grille CRT, a monochrome CRT), one or more input devices 1016 (e.g., a keyboard and/or a mouse or a gaming-like control), and one or more speakers 1018 (e.g., a speaker). In one illustrative example, the video display 1014 and the input device(s) 1016 may be combined into a single component or device (e.g., an LCD touch screen).
The one or more input devices 1016 may include a computer-readable storage medium 1020 on which the instructions 1022 embodying any one or more of the methods, operations, or functions described herein is stored. The instructions 1022 may also reside, completely or at least partially, within the main memory 1004 and/or within the processing device 1002 during execution thereof by the computer system 1000. As such, the main memory 1004 and the processing device 1002 also constitute computer-readable media. The instructions 1022 may further be transmitted or received over a network via the network interface device 1012.
While the computer-readable storage medium 1020 is shown in the illustrative examples to be a single medium, the term “computer-readable storage medium” should be taken to include a single medium or multiple media (e.g., a centralized or distributed database, and/or associated caches and servers) that store the one or more sets of instructions. The term “computer-readable storage medium” shall also be taken to include any medium that is capable of storing, encoding or carrying a set of instructions for execution by the machine and that cause the machine to perform any one or more of the methodologies of the present disclosure. The term “computer-readable storage medium” shall accordingly be taken to include, but not be limited to, solid-state memories, optical media, and magnetic media.
Consistent with the above disclosure, the examples of systems and method enumerated in the following clauses are specifically contemplated and are intended as a non-limiting set of examples.
Clause 1. A system for identifying a condition of a user, the system comprising:
a treatment apparatus configured to be manipulated by the user for performing an exercise;
Clause 2. The system of any clause herein, wherein the processing device is further configured to identify, one or more characteristics associated with the anatomical structure that is diseased.
Clause 3. The system of any clause herein, wherein the processing device is further configured to diagnose, based on the one or more characteristics, a presence of the disease and wherein the infection probability correlates with the probability of the disease being diagnosed by a medical professional.
Clause 4. The system of any clause herein, wherein the processing device is further configured to output, to the interface, a recommendation for a treatment plan based on at least one of the infection probability and the diagnosis.
Clause 5. The system of any clause herein, wherein the interface is configured to present at least one of an image or an audible or tactile signal representative of the infection probability.
Clause 6. The system of any clause herein, wherein the processing device is further configured to:
Clause 7. The system of any clause herein, wherein the interface is associated with one or more of the treatment apparatus and a medical professional.
Clause 8. The system of any clause herein, wherein the processing device is further configured to output, to the interface, a recommendation for one or more of a medication, a treatment plan, and a visit with a medical professional.
Clause 9. The system of any clause herein, wherein the visit comprises a telemedicine-enabled appointment, the telemedicine-enabled appointment characterized by the medical professional and the user not being in direct physical proximity to each other.
Clause 10. The system of any clause herein, wherein the disease is defined as an infection related to one of a surgical site or injury of the anatomical structure.
Clause 11. The system of any clause herein, wherein the processing device is further configured to:
Clause 12. The system of any clause herein, wherein the one or more inputs comprise one or more of an indication, associated with the user, of a pressure, a pain level, discoloration of a structure, and a mobility of a structure.
Clause 13. The system of any clause herein, wherein the one or more characteristics are defined as one or more etiological characteristics, and the processing device is further configured to generate the infection probability based on the one or more etiological characteristics.
Clause 14. The system of any clause herein, wherein the one or more etiological characteristics comprise at least one of a procedure or injury associated with the structure.
Clause 15. The system of an clause herein, wherein the one or more sensor inputs comprises one or more of temperature information, pressure information, discoloration information, image information, vital sign information, or measurement information.
Clause 16. The system of any clause herein, wherein the processing device is further configured to:
Clause 17. The system of any clause herein, wherein the baseline characteristic represents a state of the anatomical structure without the disease characteristic.
Clause 18. A method for identifying a condition, the method comprising:
Clause 19. The method of any clause herein, further comprising identifying one or more characteristics associated an anatomical structure having the diseased characteristics.
Clause 20. The method of any clause herein, further comprising diagnosing, based on the one or more characteristics, a presence of a disease and wherein the infection probability correlates with the probability of the disease being diagnosed by a medical professional.
Clause 21. The method of any clause herein, further comprising presenting, in the interface, a recommendation for a treatment plan based on at least one of the infection probability and the diagnosis.
Clause 22. The method of any clause herein, further comprising presenting, with the interface, at least one of an image and an audible or tactile signal representative of the infection probability.
Clause 23. The method of any clause herein, further comprising:
Clause 24. The method of any clause herein, further comprising presenting, in the interface, a recommendation for one or more of a medication, a treatment plan, and a visit with a medical professional.
Clause 25. The method of any clause herein, wherein the visit comprises a telemedicine-enabled appointment, the telemedicine-enabled appointment defined by the medical professional and the user not being in direct physical proximity to each other.
Clause 26. The method of any clause herein, further comprising:
Clause 27. A system for identifying a condition of a user, the system comprising:
Clause 28. The system of any clause herein, further comprising an interface communicatively coupled to the treatment apparatus, and wherein the processing device is further configured to:
Clause 29. The system of any clause herein, further comprising an interface communicatively coupled to the treatment apparatus, and wherein the processing device is further configured to:
Clause 30. The system of any clause herein, wherein the processing device is further configured to:
Many of the electrical connections in the drawings are shown as direct couplings having no intervening devices, but not expressly stated as such in the description above. Nevertheless, this paragraph shall serve as antecedent basis in the claims for referencing any electrical connection as “directly coupled” for electrical connections shown in the drawing with no intervening device(s).
Various functions described below can be implemented or supported by one or more computer programs, each of which is formed from computer readable program code and embodied in a computer readable storage medium. The terms “application” and “program” refer to one or more computer programs, software components, sets of instructions, procedures, functions, methods, objects, classes, instances, related data, or a portion thereof adapted for implementation in a suitable computer readable program code. The phrase “computer readable program code” includes any type of computer code, including source code, object code, and executable code. The phrase “computer readable storage medium” includes any type of medium capable of being accessed by a computer, such as read only memory (ROM), random access memory (RAM), a hard disk drive, a flash drive, a compact disc (CD), a digital video disc (DVD), solid state drive (SSD), or any other type of memory. A “non-transitory” computer readable storage medium excludes wired, wireless, optical, or other communication links that transport transitory electrical or other signals. A non-transitory computer-readable storage medium includes media where data can be permanently stored and media where data can be stored and later overwritten, such as a rewritable optical disc or an erasable memory device.
The above discussion is meant to be illustrative of the principles and various embodiments of the present invention. Once the above disclosure is fully appreciated, numerous variations and modifications will become apparent to those skilled in the art. It is intended that the following claims be interpreted to embrace all such variations and modifications.
This application is a continuation-in-part of U.S. patent application Ser. No. 17/021,895, filed Sep. 15, 2020, titled “Telemedicine for Orthopedic Treatment,” which claims priority to and the benefit of U.S. Provisional Patent Application Ser. No. 62/910,232, filed Oct. 3, 2019, titled “Telemedicine for Orthopedic Treatment,” the entire disclosures of which are hereby incorporated by reference for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4822032 | Whitmore et al. | Apr 1989 | A |
| 4860763 | Schminke | Aug 1989 | A |
| 4932650 | Bingham et al. | Jun 1990 | A |
| 5137501 | Mertesdorf | Aug 1992 | A |
| 5240417 | Smithson et al. | Aug 1993 | A |
| 5256117 | Potts et al. | Oct 1993 | A |
| 5284131 | Gray | Feb 1994 | A |
| 5318487 | Golen | Jun 1994 | A |
| 5356356 | Hildebrandt | Oct 1994 | A |
| D359777 | Hildebrandt | Jun 1995 | S |
| 5429140 | Burdea et al. | Jul 1995 | A |
| 5738636 | Saringer et al. | Apr 1998 | A |
| 6007459 | Burgess | Dec 1999 | A |
| D421075 | Hildebrandt | Feb 2000 | S |
| 6110130 | Kramer | Aug 2000 | A |
| 6162189 | Girone et al. | Dec 2000 | A |
| 6182029 | Friedman | Jan 2001 | B1 |
| 6267735 | Blanchard et al. | Jul 2001 | B1 |
| 6273863 | Avni et al. | Aug 2001 | B1 |
| 6413190 | Wood et al. | Jul 2002 | B1 |
| 6436058 | Krahner et al. | Aug 2002 | B1 |
| 6450923 | Vatti | Sep 2002 | B1 |
| 6491649 | Ombrellaro | Dec 2002 | B1 |
| 6514085 | Slattery et al. | Feb 2003 | B2 |
| 6535861 | OConnor et al. | Mar 2003 | B1 |
| 6601016 | Brown et al. | Jul 2003 | B1 |
| 6602191 | Quy | Aug 2003 | B2 |
| 6613000 | Reinkensmeyer et al. | Sep 2003 | B1 |
| 6626800 | Casler | Sep 2003 | B1 |
| 6626805 | Lightbody | Sep 2003 | B1 |
| 6640122 | Manoli | Oct 2003 | B2 |
| 6652425 | Martin et al. | Nov 2003 | B1 |
| 6890312 | Priester et al. | May 2005 | B1 |
| 6902513 | McClure | Jun 2005 | B1 |
| 7058453 | Nelson et al. | Jun 2006 | B2 |
| 7063643 | Arai | Jun 2006 | B2 |
| 7156665 | OConnor et al. | Jan 2007 | B1 |
| 7156780 | Fuchs et al. | Jan 2007 | B1 |
| 7169085 | Killin et al. | Jan 2007 | B1 |
| 7209886 | Kimmel | Apr 2007 | B2 |
| 7226394 | Johnson | Jun 2007 | B2 |
| RE39904 | Lee | Oct 2007 | E |
| 7507188 | Nurre | Mar 2009 | B2 |
| 7594879 | Johnson | Sep 2009 | B2 |
| 7628730 | Watterson et al. | Dec 2009 | B1 |
| D610635 | Hildebrandt | Feb 2010 | S |
| 7778851 | Schoenberg et al. | Aug 2010 | B2 |
| 7809601 | Shaya et al. | Oct 2010 | B2 |
| 7815551 | Merli | Oct 2010 | B2 |
| 7833135 | Radow et al. | Nov 2010 | B2 |
| 7837472 | Elsmore et al. | Nov 2010 | B1 |
| 7955219 | Birrell et al. | Jun 2011 | B2 |
| 7969315 | Ross et al. | Jun 2011 | B1 |
| 7974689 | Volpe et al. | Jul 2011 | B2 |
| 7988599 | Ainsworth et al. | Aug 2011 | B2 |
| 8012107 | Einav et al. | Sep 2011 | B2 |
| 8021270 | D'Eredita | Sep 2011 | B2 |
| 8038578 | Olrik et al. | Oct 2011 | B2 |
| 8079937 | Bedell | Dec 2011 | B2 |
| 8113991 | Kutliroff | Feb 2012 | B2 |
| 8177732 | Einav et al. | May 2012 | B2 |
| 8287434 | Zavadsky et al. | Oct 2012 | B2 |
| 8298123 | Hickman | Oct 2012 | B2 |
| 8371990 | Shea | Feb 2013 | B2 |
| 8419593 | Ainsworth et al. | Apr 2013 | B2 |
| 8465398 | Lee et al. | Jun 2013 | B2 |
| 8506458 | Dugan | Aug 2013 | B2 |
| 8515777 | Rajasenan | Aug 2013 | B1 |
| 8540515 | Williams et al. | Sep 2013 | B2 |
| 8540516 | Williams et al. | Sep 2013 | B2 |
| 8556778 | Dugan | Oct 2013 | B1 |
| 8607465 | Edwards | Dec 2013 | B1 |
| 8613689 | Dyer et al. | Dec 2013 | B2 |
| 8672812 | Dugan | Mar 2014 | B2 |
| 8751264 | Beraja et al. | Jun 2014 | B2 |
| 8784273 | Dugan | Jul 2014 | B2 |
| 8818496 | Dziubinski et al. | Aug 2014 | B2 |
| 8823448 | Shen | Sep 2014 | B1 |
| 8845493 | Watterson et al. | Sep 2014 | B2 |
| 8849681 | Hargrove et al. | Sep 2014 | B2 |
| 8864628 | Boyette et al. | Oct 2014 | B2 |
| 8893287 | Gjonej et al. | Nov 2014 | B2 |
| 8911327 | Boyette | Dec 2014 | B1 |
| 8979711 | Dugan | Mar 2015 | B2 |
| 9004598 | Weber | Apr 2015 | B2 |
| 9167281 | Petrov et al. | Oct 2015 | B2 |
| 9248071 | Brenda | Feb 2016 | B1 |
| 9272185 | Dugan | Mar 2016 | B2 |
| 9283434 | Wu | Mar 2016 | B1 |
| 9311789 | Gwin | Apr 2016 | B1 |
| 9367668 | Flynt et al. | Jun 2016 | B2 |
| 9409054 | Dugan | Aug 2016 | B2 |
| 9443205 | Wall | Sep 2016 | B2 |
| 9474935 | Abbondanza et al. | Oct 2016 | B2 |
| 9481428 | Gros | Nov 2016 | B2 |
| 9514277 | Hassing et al. | Dec 2016 | B2 |
| 9566472 | Dugan | Feb 2017 | B2 |
| 9579056 | Rosenbek et al. | Feb 2017 | B2 |
| 9629558 | Yuen et al. | Apr 2017 | B2 |
| 9640057 | Ross | May 2017 | B1 |
| 9707147 | Levital et al. | Jul 2017 | B2 |
| D794142 | Zhou | Aug 2017 | S |
| 9717947 | Lin | Aug 2017 | B2 |
| 9737761 | Govindarajan | Aug 2017 | B1 |
| 9757612 | Weber | Sep 2017 | B2 |
| 9782621 | Chiang et al. | Oct 2017 | B2 |
| 9802076 | Murray et al. | Oct 2017 | B2 |
| 9802081 | Ridgel et al. | Oct 2017 | B2 |
| 9813239 | Chee et al. | Nov 2017 | B2 |
| 9827445 | Marcos et al. | Nov 2017 | B2 |
| 9849337 | Roman et al. | Dec 2017 | B2 |
| 9868028 | Shin | Jan 2018 | B2 |
| 9872087 | DelloStritto et al. | Jan 2018 | B2 |
| 9872637 | Kording et al. | Jan 2018 | B2 |
| 9914053 | Dugan | Mar 2018 | B2 |
| 9919198 | Romeo et al. | Mar 2018 | B2 |
| 9937382 | Dugan | Apr 2018 | B2 |
| 9939784 | Berardinelli | Apr 2018 | B1 |
| 9977587 | Mountain | May 2018 | B2 |
| 9993181 | Ross | Jun 2018 | B2 |
| 10004946 | Ross | Jun 2018 | B2 |
| D826349 | Oblamski | Aug 2018 | S |
| 10055550 | Goetz | Aug 2018 | B2 |
| 10058473 | Oshima et al. | Aug 2018 | B2 |
| 10074148 | Cashman et al. | Sep 2018 | B2 |
| 10089443 | Miller et al. | Oct 2018 | B2 |
| 10111643 | Shulhauser et al. | Oct 2018 | B2 |
| 10130298 | Mokaya et al. | Nov 2018 | B2 |
| 10130311 | De Sapio et al. | Nov 2018 | B1 |
| 10137328 | Baudhuin | Nov 2018 | B2 |
| 10143395 | Chakravarthy et al. | Dec 2018 | B2 |
| 10155134 | Dugan | Dec 2018 | B2 |
| 10159872 | Sasaki et al. | Dec 2018 | B2 |
| 10173094 | Gomberg et al. | Jan 2019 | B2 |
| 10173095 | Gomberg et al. | Jan 2019 | B2 |
| 10173096 | Gomberg et al. | Jan 2019 | B2 |
| 10173097 | Gomberg et al. | Jan 2019 | B2 |
| 10198928 | Ross et al. | Feb 2019 | B1 |
| 10226663 | Gomberg et al. | Mar 2019 | B2 |
| 10231664 | Ganesh | Mar 2019 | B2 |
| 10244990 | Hu et al. | Apr 2019 | B2 |
| 10258823 | Cole | Apr 2019 | B2 |
| 10325070 | Beale et al. | Jun 2019 | B2 |
| 10327697 | Stein et al. | Jun 2019 | B1 |
| 10369021 | Zoss et al. | Aug 2019 | B2 |
| 10380866 | Ross et al. | Aug 2019 | B1 |
| 10413238 | Cooper | Sep 2019 | B1 |
| 10424033 | Romeo | Sep 2019 | B2 |
| 10430552 | Mihai | Oct 2019 | B2 |
| D866957 | Ross et al. | Nov 2019 | S |
| 10468131 | Macoviak et al. | Nov 2019 | B2 |
| 10475323 | Ross | Nov 2019 | B1 |
| 10475537 | Purdie et al. | Nov 2019 | B2 |
| 10492977 | Kapure et al. | Dec 2019 | B2 |
| 10507358 | Kinnunen et al. | Dec 2019 | B2 |
| 10542914 | Forth et al. | Jan 2020 | B2 |
| 10546467 | Luciano, Jr. et al. | Jan 2020 | B1 |
| 10569122 | Johnson | Feb 2020 | B2 |
| 10572626 | Balram | Feb 2020 | B2 |
| 10576331 | Kuo | Mar 2020 | B2 |
| 10581896 | Nachenberg | Mar 2020 | B2 |
| 10625114 | Ercanbrack | Apr 2020 | B2 |
| 10646746 | Gomberg et al. | May 2020 | B1 |
| 10660534 | Lee et al. | May 2020 | B2 |
| 10678890 | Bitran et al. | Jun 2020 | B2 |
| 10685092 | Paparella et al. | Jun 2020 | B2 |
| 10777200 | Will et al. | Sep 2020 | B2 |
| D899605 | Ross et al. | Oct 2020 | S |
| 10792495 | Izvorski et al. | Oct 2020 | B2 |
| 10867695 | Neagle | Dec 2020 | B2 |
| 10874905 | Belson et al. | Dec 2020 | B2 |
| D907143 | Ach et al. | Jan 2021 | S |
| 10881911 | Kwon et al. | Jan 2021 | B2 |
| 10918332 | Belson et al. | Feb 2021 | B2 |
| 10931643 | Neumann | Feb 2021 | B1 |
| 10987176 | Poltaretskyi et al. | Apr 2021 | B2 |
| 10991463 | Kutzko et al. | Apr 2021 | B2 |
| 11000735 | Orady et al. | May 2021 | B2 |
| 11045709 | Putnam | Jun 2021 | B2 |
| 11065170 | Yang et al. | Jul 2021 | B2 |
| 11065527 | Putnam | Jul 2021 | B2 |
| 11069436 | Mason et al. | Jul 2021 | B2 |
| 11071597 | Posnack et al. | Jul 2021 | B2 |
| 11075000 | Mason et al. | Jul 2021 | B2 |
| D928635 | Hacking et al. | Aug 2021 | S |
| 11087865 | Mason et al. | Aug 2021 | B2 |
| 11101028 | Mason et al. | Aug 2021 | B2 |
| 11107591 | Mason | Aug 2021 | B1 |
| 11139060 | Mason et al. | Oct 2021 | B2 |
| 11185735 | Arn et al. | Nov 2021 | B2 |
| D939096 | Lee | Dec 2021 | S |
| D939644 | Ach et al. | Dec 2021 | S |
| D940797 | Ach et al. | Jan 2022 | S |
| D940891 | Lee | Jan 2022 | S |
| 11229727 | Tatonetti | Jan 2022 | B2 |
| 11270795 | Mason et al. | Mar 2022 | B2 |
| 11272879 | Wiedenhoefer et al. | Mar 2022 | B2 |
| 11278766 | Lee | Mar 2022 | B2 |
| 11282599 | Mason et al. | Mar 2022 | B2 |
| 11282604 | Mason et al. | Mar 2022 | B2 |
| 11282608 | Mason et al. | Mar 2022 | B2 |
| 11284797 | Mason et al. | Mar 2022 | B2 |
| D948639 | Ach et al. | Apr 2022 | S |
| 11295848 | Mason et al. | Apr 2022 | B2 |
| 11298284 | Bayerlein | Apr 2022 | B2 |
| 11309085 | Mason et al. | Apr 2022 | B2 |
| 11317975 | Mason et al. | May 2022 | B2 |
| 11325005 | Mason et al. | May 2022 | B2 |
| 11328807 | Mason et al. | May 2022 | B2 |
| 11337648 | Mason | May 2022 | B2 |
| 11348683 | Guaneri et al. | May 2022 | B2 |
| 11376470 | Weldemariam | Jul 2022 | B2 |
| 11404150 | Guaneri et al. | Aug 2022 | B2 |
| 11410768 | Mason et al. | Aug 2022 | B2 |
| 11422841 | Jeong | Aug 2022 | B2 |
| 11495355 | McNutt et al. | Nov 2022 | B2 |
| 11508258 | Nakashima et al. | Nov 2022 | B2 |
| 11508482 | Mason et al. | Nov 2022 | B2 |
| 11515021 | Mason | Nov 2022 | B2 |
| 11515028 | Mason | Nov 2022 | B2 |
| 11524210 | Kim et al. | Dec 2022 | B2 |
| 11527326 | McNair et al. | Dec 2022 | B2 |
| 11532402 | Farley et al. | Dec 2022 | B2 |
| 11534654 | Silcock et al. | Dec 2022 | B2 |
| D976339 | Li | Jan 2023 | S |
| 11541274 | Hacking | Jan 2023 | B2 |
| 11636944 | Hanrahan et al. | Apr 2023 | B2 |
| 11663673 | Pyles | May 2023 | B2 |
| 11701548 | Posnack et al. | Jul 2023 | B2 |
| 20010044573 | Manoli | Nov 2001 | A1 |
| 20020072452 | Torkelson | Jun 2002 | A1 |
| 20020143279 | Porter et al. | Oct 2002 | A1 |
| 20020160883 | Dugan | Oct 2002 | A1 |
| 20020183599 | Castellanos | Dec 2002 | A1 |
| 20030013072 | Thomas | Jan 2003 | A1 |
| 20030036683 | Kehr et al. | Feb 2003 | A1 |
| 20030064863 | Chen | Apr 2003 | A1 |
| 20030083596 | Kramer et al. | May 2003 | A1 |
| 20030181832 | Carnahan et al. | Sep 2003 | A1 |
| 20040102931 | Ellis et al. | May 2004 | A1 |
| 20040147969 | Mann et al. | Jul 2004 | A1 |
| 20040204959 | Moreano et al. | Oct 2004 | A1 |
| 20050043153 | Krietzman | Feb 2005 | A1 |
| 20050049122 | Vallone et al. | Mar 2005 | A1 |
| 20050115561 | Stahmann | Jun 2005 | A1 |
| 20060046905 | Doody, Jr. et al. | Mar 2006 | A1 |
| 20060058648 | Meier | Mar 2006 | A1 |
| 20060064136 | Wang | Mar 2006 | A1 |
| 20060064329 | Abolfathi et al. | Mar 2006 | A1 |
| 20060199700 | LaStayo et al. | Sep 2006 | A1 |
| 20070042868 | Fisher et al. | Feb 2007 | A1 |
| 20070118389 | Shipon | May 2007 | A1 |
| 20070137307 | Gruben et al. | Jun 2007 | A1 |
| 20070173392 | Stanford | Jul 2007 | A1 |
| 20070184414 | Perez | Aug 2007 | A1 |
| 20070194939 | Alvarez et al. | Aug 2007 | A1 |
| 20070219059 | Schwartz | Sep 2007 | A1 |
| 20070287597 | Cameron | Dec 2007 | A1 |
| 20080021834 | Holla et al. | Jan 2008 | A1 |
| 20080082356 | Friedlander et al. | Apr 2008 | A1 |
| 20080096726 | Riley et al. | Apr 2008 | A1 |
| 20080153592 | James-Herbert | Jun 2008 | A1 |
| 20080161733 | Einav et al. | Jul 2008 | A1 |
| 20080281633 | Burdea et al. | Nov 2008 | A1 |
| 20080300914 | Karkanias et al. | Dec 2008 | A1 |
| 20090011907 | Radow et al. | Jan 2009 | A1 |
| 20090058635 | LaLonde et al. | Mar 2009 | A1 |
| 20090070138 | Langheier et al. | Mar 2009 | A1 |
| 20090270227 | Ashby et al. | Oct 2009 | A1 |
| 20090287503 | Angell et al. | Nov 2009 | A1 |
| 20090299766 | Friedlander et al. | Dec 2009 | A1 |
| 20100048358 | Tchao et al. | Feb 2010 | A1 |
| 20100076786 | Dalton et al. | Mar 2010 | A1 |
| 20100121160 | Stark et al. | May 2010 | A1 |
| 20100173747 | Chen et al. | Jul 2010 | A1 |
| 20100216168 | Heinzman et al. | Aug 2010 | A1 |
| 20100248899 | Bedell et al. | Sep 2010 | A1 |
| 20100268304 | Matos | Oct 2010 | A1 |
| 20100298102 | Bosecker et al. | Nov 2010 | A1 |
| 20100326207 | Topel | Dec 2010 | A1 |
| 20110010188 | Yoshikawa et al. | Jan 2011 | A1 |
| 20110047108 | Chakrabarty et al. | Feb 2011 | A1 |
| 20110119212 | De Bruin et al. | May 2011 | A1 |
| 20110172059 | Watterson et al. | Jul 2011 | A1 |
| 20110195819 | Shaw et al. | Aug 2011 | A1 |
| 20110218814 | Coats | Sep 2011 | A1 |
| 20110275483 | Dugan | Nov 2011 | A1 |
| 20110306846 | Osorio | Dec 2011 | A1 |
| 20120041771 | Cosentino et al. | Feb 2012 | A1 |
| 20120065987 | Farooq et al. | Mar 2012 | A1 |
| 20120116258 | Lee | May 2012 | A1 |
| 20120183939 | Aragones et al. | Jul 2012 | A1 |
| 20120190502 | Paulus et al. | Jul 2012 | A1 |
| 20120232438 | Cataldi et al. | Sep 2012 | A1 |
| 20120259648 | Mallon et al. | Oct 2012 | A1 |
| 20120295240 | Walker et al. | Nov 2012 | A1 |
| 20120296455 | Ohnemus et al. | Nov 2012 | A1 |
| 20120310667 | Altman et al. | Dec 2012 | A1 |
| 20130123667 | Komatireddy et al. | May 2013 | A1 |
| 20130137550 | Skinner et al. | May 2013 | A1 |
| 20130178334 | Brammer | Jul 2013 | A1 |
| 20130211281 | Ross et al. | Aug 2013 | A1 |
| 20130253943 | Lee et al. | Sep 2013 | A1 |
| 20130274069 | Watterson et al. | Oct 2013 | A1 |
| 20130296987 | Rogers et al. | Nov 2013 | A1 |
| 20130318027 | Almogy et al. | Nov 2013 | A1 |
| 20130332616 | Landwehr | Dec 2013 | A1 |
| 20130345025 | van der Merwe | Dec 2013 | A1 |
| 20140006042 | Keefe et al. | Jan 2014 | A1 |
| 20140011640 | Dugan | Jan 2014 | A1 |
| 20140089836 | Damani et al. | Mar 2014 | A1 |
| 20140113768 | Lin et al. | Apr 2014 | A1 |
| 20140155129 | Dugan | Jun 2014 | A1 |
| 20140172442 | Broderick | Jun 2014 | A1 |
| 20140172460 | Kohli | Jun 2014 | A1 |
| 20140188009 | Lange et al. | Jul 2014 | A1 |
| 20140194250 | Reich et al. | Jul 2014 | A1 |
| 20140194251 | Reich et al. | Jul 2014 | A1 |
| 20140207264 | Quy | Jul 2014 | A1 |
| 20140207486 | Carty et al. | Jul 2014 | A1 |
| 20140228649 | Rayner et al. | Aug 2014 | A1 |
| 20140246499 | Proud et al. | Sep 2014 | A1 |
| 20140256511 | Smith | Sep 2014 | A1 |
| 20140257837 | Walker et al. | Sep 2014 | A1 |
| 20140274565 | Boyette et al. | Sep 2014 | A1 |
| 20140274622 | Leonhard | Sep 2014 | A1 |
| 20140303540 | Baym | Oct 2014 | A1 |
| 20140309083 | Dugan | Oct 2014 | A1 |
| 20140315689 | Vauquelin et al. | Oct 2014 | A1 |
| 20140322686 | Kang | Oct 2014 | A1 |
| 20140371816 | Matos | Dec 2014 | A1 |
| 20150025816 | Ross | Jan 2015 | A1 |
| 20150045700 | Cavanagh et al. | Feb 2015 | A1 |
| 20150073814 | Linebaugh | Mar 2015 | A1 |
| 20150088544 | Goldberg | Mar 2015 | A1 |
| 20150094192 | Skwortsow et al. | Apr 2015 | A1 |
| 20150099458 | Weisner et al. | Apr 2015 | A1 |
| 20150099952 | Lain et al. | Apr 2015 | A1 |
| 20150112230 | Iglesias | Apr 2015 | A1 |
| 20150130830 | Nagasaki | May 2015 | A1 |
| 20150141200 | Murray et al. | May 2015 | A1 |
| 20150149217 | Kaburagi | May 2015 | A1 |
| 20150151162 | Dugan | Jun 2015 | A1 |
| 20150158549 | Gros et al. | Jun 2015 | A1 |
| 20150161331 | Oleynik | Jun 2015 | A1 |
| 20150196805 | Koduri | Jul 2015 | A1 |
| 20150257679 | Ross | Sep 2015 | A1 |
| 20150265209 | Zhang | Sep 2015 | A1 |
| 20150290061 | Stafford et al. | Oct 2015 | A1 |
| 20150339442 | Oleynik | Nov 2015 | A1 |
| 20150341812 | Dion et al. | Nov 2015 | A1 |
| 20150351664 | Ross | Dec 2015 | A1 |
| 20150351665 | Ross | Dec 2015 | A1 |
| 20150360069 | Marti et al. | Dec 2015 | A1 |
| 20150379232 | Mainwaring et al. | Dec 2015 | A1 |
| 20150379430 | Dirac et al. | Dec 2015 | A1 |
| 20160007885 | Basta | Jan 2016 | A1 |
| 20160045170 | Migita | Feb 2016 | A1 |
| 20160096073 | Rahman et al. | Apr 2016 | A1 |
| 20160117471 | Belt et al. | Apr 2016 | A1 |
| 20160140319 | Stark | May 2016 | A1 |
| 20160143593 | Fu et al. | May 2016 | A1 |
| 20160151670 | Dugan | Jun 2016 | A1 |
| 20160166833 | Bum | Jun 2016 | A1 |
| 20160166881 | Ridgel et al. | Jun 2016 | A1 |
| 20160193306 | Rabovsky et al. | Jul 2016 | A1 |
| 20160213924 | Coleman | Jul 2016 | A1 |
| 20160275259 | Nolan et al. | Sep 2016 | A1 |
| 20160287166 | Tran | Oct 2016 | A1 |
| 20160302721 | Wiedenhoefer et al. | Oct 2016 | A1 |
| 20160317869 | Dugan | Nov 2016 | A1 |
| 20160322078 | Bose et al. | Nov 2016 | A1 |
| 20160325140 | Wu | Nov 2016 | A1 |
| 20160332028 | Melnik | Nov 2016 | A1 |
| 20160354636 | Jang | Dec 2016 | A1 |
| 20160361597 | Cole et al. | Dec 2016 | A1 |
| 20160373477 | Moyle | Dec 2016 | A1 |
| 20170004260 | Moturu et al. | Jan 2017 | A1 |
| 20170033375 | Ohmori et al. | Feb 2017 | A1 |
| 20170042467 | Herr et al. | Feb 2017 | A1 |
| 20170046488 | Pereira | Feb 2017 | A1 |
| 20170065851 | Deluca et al. | Mar 2017 | A1 |
| 20170080320 | Smith | Mar 2017 | A1 |
| 20170095670 | Ghaffari et al. | Apr 2017 | A1 |
| 20170095692 | Chang et al. | Apr 2017 | A1 |
| 20170095693 | Chang et al. | Apr 2017 | A1 |
| 20170100637 | Princen et al. | Apr 2017 | A1 |
| 20170106242 | Dugan | Apr 2017 | A1 |
| 20170128769 | Long et al. | May 2017 | A1 |
| 20170132947 | Maeda et al. | May 2017 | A1 |
| 20170136296 | Barrera et al. | May 2017 | A1 |
| 20170143261 | Wiedenhoefer et al. | May 2017 | A1 |
| 20170147752 | Toru | May 2017 | A1 |
| 20170147789 | Wiedenhoefer et al. | May 2017 | A1 |
| 20170148297 | Ross | May 2017 | A1 |
| 20170168555 | Munoz et al. | Jun 2017 | A1 |
| 20170181698 | Wiedenhoefer et al. | Jun 2017 | A1 |
| 20170190052 | Jaekel et al. | Jul 2017 | A1 |
| 20170202724 | De Rossi | Jul 2017 | A1 |
| 20170209766 | Riley et al. | Jul 2017 | A1 |
| 20170220751 | Davis | Aug 2017 | A1 |
| 20170235882 | Orlov et al. | Aug 2017 | A1 |
| 20170235906 | Dorris et al. | Aug 2017 | A1 |
| 20170243028 | LaFever et al. | Aug 2017 | A1 |
| 20170262604 | Francois | Sep 2017 | A1 |
| 20170266501 | Sanders et al. | Sep 2017 | A1 |
| 20170270260 | Shetty | Sep 2017 | A1 |
| 20170278209 | Olsen et al. | Sep 2017 | A1 |
| 20170282015 | Wicks et al. | Oct 2017 | A1 |
| 20170283508 | Demopulos et al. | Oct 2017 | A1 |
| 20170286621 | Cox | Oct 2017 | A1 |
| 20170300654 | Stein et al. | Oct 2017 | A1 |
| 20170304024 | Nobrega | Oct 2017 | A1 |
| 20170312614 | Tran et al. | Nov 2017 | A1 |
| 20170323481 | Tran et al. | Nov 2017 | A1 |
| 20170329917 | McRaith et al. | Nov 2017 | A1 |
| 20170329933 | Brust | Nov 2017 | A1 |
| 20170333755 | Rider | Nov 2017 | A1 |
| 20170337033 | Duyan et al. | Nov 2017 | A1 |
| 20170337334 | Stanczak | Nov 2017 | A1 |
| 20170344726 | Duffy et al. | Nov 2017 | A1 |
| 20170347923 | Roh | Dec 2017 | A1 |
| 20170360586 | Dempers et al. | Dec 2017 | A1 |
| 20170368413 | Shavit | Dec 2017 | A1 |
| 20180017806 | Wang et al. | Jan 2018 | A1 |
| 20180036593 | Ridgel et al. | Feb 2018 | A1 |
| 20180052962 | Van Der Koijk et al. | Feb 2018 | A1 |
| 20180056104 | Cromie et al. | Mar 2018 | A1 |
| 20180060494 | Dias et al. | Mar 2018 | A1 |
| 20180071572 | Gomberg et al. | Mar 2018 | A1 |
| 20180075205 | Moturu et al. | Mar 2018 | A1 |
| 20180078843 | Tran et al. | Mar 2018 | A1 |
| 20180085615 | Astolfi et al. | Mar 2018 | A1 |
| 20180096111 | Wells et al. | Apr 2018 | A1 |
| 20180102190 | Hogue et al. | Apr 2018 | A1 |
| 20180116741 | Garcia Kilroy et al. | May 2018 | A1 |
| 20180140927 | Kito | May 2018 | A1 |
| 20180146870 | Shemesh | May 2018 | A1 |
| 20180177612 | Trabish et al. | Jun 2018 | A1 |
| 20180178061 | O'larte et al. | Jun 2018 | A1 |
| 20180199855 | Odame et al. | Jul 2018 | A1 |
| 20180200577 | Dugan | Jul 2018 | A1 |
| 20180220935 | Tadano et al. | Aug 2018 | A1 |
| 20180228682 | Bayerlein et al. | Aug 2018 | A1 |
| 20180240552 | Tuyl et al. | Aug 2018 | A1 |
| 20180253991 | Tang et al. | Sep 2018 | A1 |
| 20180256079 | Yang et al. | Sep 2018 | A1 |
| 20180263530 | Jung | Sep 2018 | A1 |
| 20180263535 | Cramer | Sep 2018 | A1 |
| 20180263552 | Graman et al. | Sep 2018 | A1 |
| 20180264312 | Pompile et al. | Sep 2018 | A1 |
| 20180271432 | Auchinleck et al. | Sep 2018 | A1 |
| 20180272184 | Vassilaros et al. | Sep 2018 | A1 |
| 20180280784 | Romeo et al. | Oct 2018 | A1 |
| 20180296143 | Anderson et al. | Oct 2018 | A1 |
| 20180296157 | Bleich et al. | Oct 2018 | A1 |
| 20180326243 | Badi et al. | Nov 2018 | A1 |
| 20180330058 | Bates | Nov 2018 | A1 |
| 20180330810 | Gamarnik | Nov 2018 | A1 |
| 20180330824 | Athey et al. | Nov 2018 | A1 |
| 20180290017 | Fung | Dec 2018 | A1 |
| 20180353812 | Lannon et al. | Dec 2018 | A1 |
| 20180360340 | Rehse et al. | Dec 2018 | A1 |
| 20180373844 | Ferrandez-Escamez et al. | Dec 2018 | A1 |
| 20190009135 | Wu | Jan 2019 | A1 |
| 20190019163 | Batey et al. | Jan 2019 | A1 |
| 20190019573 | Lake et al. | Jan 2019 | A1 |
| 20190019578 | Vaccaro | Jan 2019 | A1 |
| 20190030415 | Volpe, Jr. | Jan 2019 | A1 |
| 20190031284 | Fuchs | Jan 2019 | A1 |
| 20190046794 | Goodall et al. | Feb 2019 | A1 |
| 20190060708 | Fung | Feb 2019 | A1 |
| 20190065970 | Bonutti et al. | Feb 2019 | A1 |
| 20190066832 | Kang et al. | Feb 2019 | A1 |
| 20190076701 | Dugan | Mar 2019 | A1 |
| 20190080802 | Ziobro et al. | Mar 2019 | A1 |
| 20190088356 | Oliver et al. | Mar 2019 | A1 |
| 20190090744 | Mahfouz | Mar 2019 | A1 |
| 20190111299 | Radcliffe et al. | Apr 2019 | A1 |
| 20190115097 | Macoviak et al. | Apr 2019 | A1 |
| 20190117128 | Chen et al. | Apr 2019 | A1 |
| 20190118038 | Tana et al. | Apr 2019 | A1 |
| 20190126099 | Hoang | May 2019 | A1 |
| 20190132948 | Longinotti-Buitoni et al. | May 2019 | A1 |
| 20190134454 | Mahoney et al. | May 2019 | A1 |
| 20190137988 | Cella et al. | May 2019 | A1 |
| 20190167988 | Shahriari et al. | Jun 2019 | A1 |
| 20190172587 | Park et al. | Jun 2019 | A1 |
| 20190175988 | Volterrani et al. | Jun 2019 | A1 |
| 20190183715 | Kapure | Jun 2019 | A1 |
| 20190200920 | Tien et al. | Jul 2019 | A1 |
| 20190209891 | Fung | Jul 2019 | A1 |
| 20190223797 | Tran | Jul 2019 | A1 |
| 20190228856 | Leifer | Jul 2019 | A1 |
| 20190240103 | Hepler et al. | Aug 2019 | A1 |
| 20190240541 | Denton et al. | Aug 2019 | A1 |
| 20190244540 | Errante et al. | Aug 2019 | A1 |
| 20190251456 | Constantin | Aug 2019 | A1 |
| 20190262084 | Roh | Aug 2019 | A1 |
| 20190269343 | Ramos Murguialday et al. | Sep 2019 | A1 |
| 20190274523 | Bates et al. | Sep 2019 | A1 |
| 20190275368 | Maroldi | Sep 2019 | A1 |
| 20190290964 | Oren | Sep 2019 | A1 |
| 20190304584 | Savolainen | Oct 2019 | A1 |
| 20190307983 | Goldman | Oct 2019 | A1 |
| 20190314681 | Yang | Oct 2019 | A1 |
| 20190344123 | Rubin et al. | Nov 2019 | A1 |
| 20190354632 | Mital et al. | Nov 2019 | A1 |
| 20190362242 | Pillai et al. | Nov 2019 | A1 |
| 20190366146 | Tong et al. | Dec 2019 | A1 |
| 20190388728 | Wang et al. | Dec 2019 | A1 |
| 20200005928 | Daniel | Jan 2020 | A1 |
| 20200038703 | Cleary et al. | Feb 2020 | A1 |
| 20200051446 | Rubinstein et al. | Feb 2020 | A1 |
| 20200066390 | Svendrys et al. | Feb 2020 | A1 |
| 20200085300 | Kwatra et al. | Mar 2020 | A1 |
| 20200093418 | Kluger et al. | Mar 2020 | A1 |
| 20200143922 | Chekroud et al. | May 2020 | A1 |
| 20200151595 | Jayalath et al. | May 2020 | A1 |
| 20200151646 | De La Fuente Sanchez | May 2020 | A1 |
| 20200152339 | Pulitzer et al. | May 2020 | A1 |
| 20200160198 | Reeves et al. | May 2020 | A1 |
| 20200170876 | Kapure et al. | Jun 2020 | A1 |
| 20200176098 | Lucas et al. | Jun 2020 | A1 |
| 20200197744 | Schweighofer | Jun 2020 | A1 |
| 20200221975 | Basta et al. | Jul 2020 | A1 |
| 20200237291 | Raja | Jul 2020 | A1 |
| 20200267487 | Siva | Aug 2020 | A1 |
| 20200275886 | Mason | Sep 2020 | A1 |
| 20200289045 | Hacking et al. | Sep 2020 | A1 |
| 20200289046 | Hacking et al. | Sep 2020 | A1 |
| 20200289879 | Hacking et al. | Sep 2020 | A1 |
| 20200289880 | Hacking et al. | Sep 2020 | A1 |
| 20200289881 | Hacking et al. | Sep 2020 | A1 |
| 20200289889 | Hacking et al. | Sep 2020 | A1 |
| 20200293712 | Potts et al. | Sep 2020 | A1 |
| 20200303063 | Sharma et al. | Sep 2020 | A1 |
| 20200334972 | Gopalakrishnan | Oct 2020 | A1 |
| 20200357299 | Patel et al. | Nov 2020 | A1 |
| 20200365256 | Hayashitani et al. | Nov 2020 | A1 |
| 20200395112 | Ronner | Dec 2020 | A1 |
| 20200401224 | Cotton | Dec 2020 | A1 |
| 20200410385 | Otsuki | Dec 2020 | A1 |
| 20200411162 | Lien et al. | Dec 2020 | A1 |
| 20210005224 | Rothschild et al. | Jan 2021 | A1 |
| 20210005319 | Otsuki et al. | Jan 2021 | A1 |
| 20210035674 | Volosin et al. | Feb 2021 | A1 |
| 20210074178 | Ilan et al. | Mar 2021 | A1 |
| 20210076981 | Hacking et al. | Mar 2021 | A1 |
| 20210077860 | Posnack et al. | Mar 2021 | A1 |
| 20210098129 | Neumann | Apr 2021 | A1 |
| 20210101051 | Posnack et al. | Apr 2021 | A1 |
| 20210113890 | Posnack et al. | Apr 2021 | A1 |
| 20210127974 | Mason et al. | May 2021 | A1 |
| 20210128080 | Mason et al. | May 2021 | A1 |
| 20210128255 | Mason et al. | May 2021 | A1 |
| 20210128978 | Gilstrom et al. | May 2021 | A1 |
| 20210134412 | Guaneri et al. | May 2021 | A1 |
| 20210134425 | Mason et al. | May 2021 | A1 |
| 20210134428 | Mason et al. | May 2021 | A1 |
| 20210134430 | Mason et al. | May 2021 | A1 |
| 20210134432 | Mason et al. | May 2021 | A1 |
| 20210134456 | Posnack et al. | May 2021 | A1 |
| 20210134457 | Mason et al. | May 2021 | A1 |
| 20210134458 | Mason et al. | May 2021 | A1 |
| 20210138304 | Mason et al. | May 2021 | A1 |
| 20210142875 | Mason et al. | May 2021 | A1 |
| 20210142893 | Guaneri et al. | May 2021 | A1 |
| 20210142898 | Mason et al. | May 2021 | A1 |
| 20210142903 | Mason et al. | May 2021 | A1 |
| 20210144074 | Guaneri et al. | May 2021 | A1 |
| 20210186419 | Van Ee et al. | Jun 2021 | A1 |
| 20210202090 | ODonovan et al. | Jul 2021 | A1 |
| 20210202103 | Bostic et al. | Jul 2021 | A1 |
| 20210244998 | Hacking et al. | Aug 2021 | A1 |
| 20210245003 | Turner | Aug 2021 | A1 |
| 20210251562 | Jain | Aug 2021 | A1 |
| 20210272677 | Barbee | Sep 2021 | A1 |
| 20210338469 | Dempers | Nov 2021 | A1 |
| 20210343384 | Purushothaman et al. | Nov 2021 | A1 |
| 20210345879 | Mason et al. | Nov 2021 | A1 |
| 20210345975 | Mason et al. | Nov 2021 | A1 |
| 20210350888 | Guaneri et al. | Nov 2021 | A1 |
| 20210350898 | Mason et al. | Nov 2021 | A1 |
| 20210350899 | Mason et al. | Nov 2021 | A1 |
| 20210350901 | Mason et al. | Nov 2021 | A1 |
| 20210350902 | Mason et al. | Nov 2021 | A1 |
| 20210350914 | Guaneri et al. | Nov 2021 | A1 |
| 20210350926 | Mason et al. | Nov 2021 | A1 |
| 20210361514 | Choi et al. | Nov 2021 | A1 |
| 20210366587 | Mason et al. | Nov 2021 | A1 |
| 20210383909 | Mason et al. | Dec 2021 | A1 |
| 20210391091 | Mason | Dec 2021 | A1 |
| 20210398668 | Chock et al. | Dec 2021 | A1 |
| 20210407670 | Mason et al. | Dec 2021 | A1 |
| 20210407681 | Mason et al. | Dec 2021 | A1 |
| 20220000556 | Casey et al. | Jan 2022 | A1 |
| 20220015838 | Posnack et al. | Jan 2022 | A1 |
| 20220016480 | Bissonnette et al. | Jan 2022 | A1 |
| 20220016482 | Bissonnette | Jan 2022 | A1 |
| 20220016485 | Bissonnette et al. | Jan 2022 | A1 |
| 20220016486 | Bissonnette | Jan 2022 | A1 |
| 20220020469 | Tanner | Jan 2022 | A1 |
| 20220044806 | Sanders et al. | Feb 2022 | A1 |
| 20220047921 | Bissonnette et al. | Feb 2022 | A1 |
| 20220079690 | Mason et al. | Mar 2022 | A1 |
| 20220080256 | Arn et al. | Mar 2022 | A1 |
| 20220080265 | Watterson | Mar 2022 | A1 |
| 20220105384 | Hacking et al. | Apr 2022 | A1 |
| 20220105385 | Hacking et al. | Apr 2022 | A1 |
| 20220105390 | Yuasa | Apr 2022 | A1 |
| 20220115133 | Mason et al. | Apr 2022 | A1 |
| 20220118218 | Bense et al. | Apr 2022 | A1 |
| 20220126169 | Mason | Apr 2022 | A1 |
| 20220133576 | Choi et al. | May 2022 | A1 |
| 20220148725 | Mason et al. | May 2022 | A1 |
| 20220158916 | Mason et al. | May 2022 | A1 |
| 20220176039 | Lintereur et al. | Jun 2022 | A1 |
| 20220181004 | Zilca et al. | Jun 2022 | A1 |
| 20220193491 | Mason et al. | Jun 2022 | A1 |
| 20220230729 | Mason et al. | Jul 2022 | A1 |
| 20220238222 | Neuberg | Jul 2022 | A1 |
| 20220238223 | Mason et al. | Jul 2022 | A1 |
| 20220262483 | Rosenberg et al. | Aug 2022 | A1 |
| 20220262504 | Bratty et al. | Aug 2022 | A1 |
| 20220266094 | Mason et al. | Aug 2022 | A1 |
| 20220270738 | Mason et al. | Aug 2022 | A1 |
| 20220273985 | Jeong et al. | Sep 2022 | A1 |
| 20220273986 | Mason | Sep 2022 | A1 |
| 20220288460 | Mason | Sep 2022 | A1 |
| 20220288461 | Ashley et al. | Sep 2022 | A1 |
| 20220288462 | Ashley et al. | Sep 2022 | A1 |
| 20220293257 | Guaneri et al. | Sep 2022 | A1 |
| 20220300787 | Wall et al. | Sep 2022 | A1 |
| 20220304881 | Choi et al. | Sep 2022 | A1 |
| 20220304882 | Choi | Sep 2022 | A1 |
| 20220305328 | Choi et al. | Sep 2022 | A1 |
| 20220314075 | Mason et al. | Oct 2022 | A1 |
| 20220323826 | Khurana | Oct 2022 | A1 |
| 20220327714 | Cook et al. | Oct 2022 | A1 |
| 20220327807 | Cook et al. | Oct 2022 | A1 |
| 20220328181 | Mason et al. | Oct 2022 | A1 |
| 20220330823 | Janssen | Oct 2022 | A1 |
| 20220331663 | Mason | Oct 2022 | A1 |
| 20220338761 | Maddahi et al. | Oct 2022 | A1 |
| 20220339052 | Kim | Oct 2022 | A1 |
| 20220339501 | Mason et al. | Oct 2022 | A1 |
| 20220384012 | Mason | Dec 2022 | A1 |
| 20220392591 | Guaneri et al. | Dec 2022 | A1 |
| 20220395232 | Locke | Dec 2022 | A1 |
| 20220401783 | Choi | Dec 2022 | A1 |
| 20220415469 | Mason | Dec 2022 | A1 |
| 20220415471 | Mason | Dec 2022 | A1 |
| 20230001268 | Bissonnette et al. | Jan 2023 | A1 |
| 20230013530 | Mason | Jan 2023 | A1 |
| 20230014598 | Mason et al. | Jan 2023 | A1 |
| 20230029639 | Roy | Feb 2023 | A1 |
| 20230048040 | Hacking et al. | Feb 2023 | A1 |
| 20230051751 | Hacking et al. | Feb 2023 | A1 |
| 20230058605 | Mason | Feb 2023 | A1 |
| 20230060039 | Mason | Feb 2023 | A1 |
| 20230072368 | Mason | Mar 2023 | A1 |
| 20230078793 | Mason | Mar 2023 | A1 |
| 20230119461 | Mason | Apr 2023 | A1 |
| 20230190100 | Stump | Jun 2023 | A1 |
| 20230201656 | Hacking et al. | Jun 2023 | A1 |
| 20230207097 | Mason | Jun 2023 | A1 |
| 20230207124 | Walsh et al. | Jun 2023 | A1 |
| 20230215539 | Rosenberg et al. | Jul 2023 | A1 |
| 20230215552 | Khotilovich et al. | Jul 2023 | A1 |
| 20230245747 | Rosenberg et al. | Aug 2023 | A1 |
| 20230245748 | Rosenberg et al. | Aug 2023 | A1 |
| 20230245750 | Rosenberg et al. | Aug 2023 | A1 |
| 20230245751 | Rosenberg et al. | Aug 2023 | A1 |
| 20230253089 | Rosenberg et al. | Aug 2023 | A1 |
| 20230255555 | Sundaram et al. | Aug 2023 | A1 |
| 20230263428 | Hull et al. | Aug 2023 | A1 |
| 20230274813 | Rosenberg et al. | Aug 2023 | A1 |
| 20230282329 | Mason et al. | Sep 2023 | A1 |
| 20230364472 | Posnack | Nov 2023 | A1 |
| 20230368886 | Rosenberg | Nov 2023 | A1 |
| 20230377711 | Rosenberg | Nov 2023 | A1 |
| 20230377712 | Rosenberg | Nov 2023 | A1 |
| 20230386639 | Rosenberg | Nov 2023 | A1 |
| 20230395231 | Rosenberg | Dec 2023 | A1 |
| 20230395232 | Rosenberg | Dec 2023 | A1 |
| 20240029856 | Rosenberg | Jan 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 2698078 | Mar 2010 | CA |
| 3193419 | Mar 2022 | CA |
| 112603295 | Feb 2003 | CN |
| 2885238 | Apr 2007 | CN |
| 101964151 | Feb 2011 | CN |
| 201889024 | Jul 2011 | CN |
| 102670381 | Sep 2012 | CN |
| 103263336 | Aug 2013 | CN |
| 103390357 | Nov 2013 | CN |
| 103473631 | Dec 2013 | CN |
| 103488880 | Jan 2014 | CN |
| 103501328 | Jan 2014 | CN |
| 103721343 | Apr 2014 | CN |
| 203677851 | Jul 2014 | CN |
| 104335211 | Feb 2015 | CN |
| 105683977 | Jun 2016 | CN |
| 103136447 | Aug 2016 | CN |
| 105894088 | Aug 2016 | CN |
| 105930668 | Sep 2016 | CN |
| 205626871 | Oct 2016 | CN |
| 106127646 | Nov 2016 | CN |
| 106236502 | Dec 2016 | CN |
| 106510985 | Mar 2017 | CN |
| 106621195 | May 2017 | CN |
| 107066819 | Aug 2017 | CN |
| 107430641 | Dec 2017 | CN |
| 107551475 | Jan 2018 | CN |
| 107736982 | Feb 2018 | CN |
| 107930021 | Apr 2018 | CN |
| 207220817 | Apr 2018 | CN |
| 108078737 | May 2018 | CN |
| 208224811 | Dec 2018 | CN |
| 109191954 | Jan 2019 | CN |
| 109363887 | Feb 2019 | CN |
| 208573971 | Mar 2019 | CN |
| 110148472 | Aug 2019 | CN |
| 110201358 | Sep 2019 | CN |
| 110215188 | Sep 2019 | CN |
| 110322957 | Oct 2019 | CN |
| 110808092 | Feb 2020 | CN |
| 110931103 | Mar 2020 | CN |
| 110993057 | Apr 2020 | CN |
| 111105859 | May 2020 | CN |
| 111111110 | May 2020 | CN |
| 111370088 | Jul 2020 | CN |
| 111460305 | Jul 2020 | CN |
| 111790111 | Oct 2020 | CN |
| 112071393 | Dec 2020 | CN |
| 212141371 | Dec 2020 | CN |
| 112289425 | Jan 2021 | CN |
| 212624809 | Feb 2021 | CN |
| 112603295 | Apr 2021 | CN |
| 213190965 | May 2021 | CN |
| 113384850 | Sep 2021 | CN |
| 113499572 | Oct 2021 | CN |
| 215136488 | Dec 2021 | CN |
| 113885361 | Jan 2022 | CN |
| 114049961 | Feb 2022 | CN |
| 114203274 | Mar 2022 | CN |
| 216258145 | Apr 2022 | CN |
| 114632302 | Jun 2022 | CN |
| 114694824 | Jul 2022 | CN |
| 114898832 | Aug 2022 | CN |
| 114983760 | Sep 2022 | CN |
| 217472652 | Sep 2022 | CN |
| 110270062 | Oct 2022 | CN |
| 218420859 | Feb 2023 | CN |
| 115954081 | Apr 2023 | CN |
| 102018202497 | Aug 2018 | DE |
| 102018211212 | Jan 2019 | DE |
| 102019108425 | Aug 2020 | DE |
| 0383137 | Aug 1990 | EP |
| 1159989 | Dec 2001 | EP |
| 1391179 | Feb 2004 | EP |
| 1968028 | Sep 2008 | EP |
| 1909730 | Apr 2014 | EP |
| 2815242 | Dec 2014 | EP |
| 2869805 | May 2015 | EP |
| 2997951 | Mar 2016 | EP |
| 2688472 | Apr 2016 | EP |
| 3323473 | May 2018 | EP |
| 3627514 | Mar 2020 | EP |
| 3671700 | Jun 2020 | EP |
| 3688537 | Aug 2020 | EP |
| 3731733 | Nov 2020 | EP |
| 3984508 | Apr 2022 | EP |
| 3984509 | Apr 2022 | EP |
| 3984510 | Apr 2022 | EP |
| 3984511 | Apr 2022 | EP |
| 3984512 | Apr 2022 | EP |
| 3984513 | Apr 2022 | EP |
| 4054699 | Sep 2022 | EP |
| 4112033 | Jan 2023 | EP |
| 3127393 | Mar 2023 | FR |
| 2512431 | Oct 2014 | GB |
| 2591542 | Mar 2022 | GB |
| 201811043670 | Jul 2018 | IN |
| 2000005339 | Jan 2000 | JP |
| 2003225875 | Aug 2003 | JP |
| 2005227928 | Aug 2005 | JP |
| 2005227928 | Aug 2005 | JP |
| 2009112336 | May 2009 | JP |
| 2013515995 | May 2013 | JP |
| 3193662 | Oct 2014 | JP |
| 3198173 | Jun 2015 | JP |
| 5804063 | Nov 2015 | JP |
| 6659831 | Oct 2017 | JP |
| 2018102842 | Jul 2018 | JP |
| 2019028647 | Feb 2019 | JP |
| 2019134909 | Aug 2019 | JP |
| 6573739 | Sep 2019 | JP |
| 6710357 | Jun 2020 | JP |
| 6775757 | Oct 2020 | JP |
| 2021026768 | Feb 2021 | JP |
| 2021027917 | Feb 2021 | JP |
| 6871379 | May 2021 | JP |
| 2022521378 | Apr 2022 | JP |
| 3238491 | Jul 2022 | JP |
| 7198364 | Dec 2022 | JP |
| 7202474 | Jan 2023 | JP |
| 7231750 | Mar 2023 | JP |
| 7231751 | Mar 2023 | JP |
| 7231752 | Mar 2023 | JP |
| 20020009724 | Feb 2002 | KR |
| 200276919 | May 2002 | KR |
| 20020065253 | Aug 2002 | KR |
| 100582596 | May 2006 | KR |
| 101042258 | Jun 2011 | KR |
| 20110099953 | Sep 2011 | KR |
| 101258250 | Apr 2013 | KR |
| 101325581 | Nov 2013 | KR |
| 20140128630 | Nov 2014 | KR |
| 20150017693 | Feb 2015 | KR |
| 20150078191 | Jul 2015 | KR |
| 101580071 | Dec 2015 | KR |
| 101647620 | Aug 2016 | KR |
| 20160093990 | Aug 2016 | KR |
| 20170038837 | Apr 2017 | KR |
| 20180004928 | Jan 2018 | KR |
| 20190011885 | Feb 2019 | KR |
| 20190029175 | Mar 2019 | KR |
| 101988167 | Jun 2019 | KR |
| 102116664 | Jul 2019 | KR |
| 101969392 | Aug 2019 | KR |
| 102055279 | Dec 2019 | KR |
| 102088333 | Mar 2020 | KR |
| 102116968 | Mar 2020 | KR |
| 20200025290 | Mar 2020 | KR |
| 20200029180 | Mar 2020 | KR |
| 102162522 | Apr 2020 | KR |
| 102142713 | May 2020 | KR |
| 20200056233 | May 2020 | KR |
| 102120828 | Jun 2020 | KR |
| 102121586 | Jun 2020 | KR |
| 20200119665 | Oct 2020 | KR |
| 102173553 | Nov 2020 | KR |
| 102180079 | Nov 2020 | KR |
| 102224618 | Nov 2020 | KR |
| 102188766 | Dec 2020 | KR |
| 102196793 | Dec 2020 | KR |
| 20210006212 | Jan 2021 | KR |
| 102224188 | Mar 2021 | KR |
| 102246049 | Apr 2021 | KR |
| 102246050 | Apr 2021 | KR |
| 102246051 | Apr 2021 | KR |
| 102246052 | Apr 2021 | KR |
| 20210052028 | May 2021 | KR |
| 102264498 | Jun 2021 | KR |
| 102352602 | Jan 2022 | KR |
| 102352603 | Jan 2022 | KR |
| 102352604 | Jan 2022 | KR |
| 20220004639 | Jan 2022 | KR |
| 102387577 | Apr 2022 | KR |
| 102421437 | Jul 2022 | KR |
| 20220102207 | Jul 2022 | KR |
| 102427545 | Aug 2022 | KR |
| 102467495 | Nov 2022 | KR |
| 102467496 | Nov 2022 | KR |
| 102469723 | Nov 2022 | KR |
| 102471990 | Nov 2022 | KR |
| 20220145989 | Nov 2022 | KR |
| 20220156134 | Nov 2022 | KR |
| 102502744 | Feb 2023 | KR |
| 20230019349 | Feb 2023 | KR |
| 20230019350 | Feb 2023 | KR |
| 20230026556 | Feb 2023 | KR |
| 20230026668 | Feb 2023 | KR |
| 20230040526 | Mar 2023 | KR |
| 20230050506 | Apr 2023 | KR |
| 20230056118 | Apr 2023 | KR |
| 102528503 | May 2023 | KR |
| 102531930 | May 2023 | KR |
| 102532766 | May 2023 | KR |
| 102539190 | Jun 2023 | KR |
| 2014131288 | Feb 2016 | RU |
| 2607953 | Jan 2017 | RU |
| M474545 | Mar 2014 | TW |
| M638437 | Mar 2023 | TW |
| 0149235 | Jul 2001 | WO |
| 0151083 | Jul 2001 | WO |
| 2001050387 | Jul 2001 | WO |
| 2001056465 | Aug 2001 | WO |
| 02062211 | Aug 2002 | WO |
| 02093312 | Nov 2002 | WO |
| 2003043494 | May 2003 | WO |
| 2005018453 | Mar 2005 | WO |
| 2006004430 | Jan 2006 | WO |
| 2007102709 | Sep 2007 | WO |
| 2008114291 | Sep 2008 | WO |
| 2009008968 | Jan 2009 | WO |
| 2011025322 | Mar 2011 | WO |
| 2012128801 | Sep 2012 | WO |
| 2013002568 | Jan 2013 | WO |
| 2023164292 | Mar 2013 | WO |
| 2013122839 | Aug 2013 | WO |
| 2014011447 | Jan 2014 | WO |
| 2014163976 | Oct 2014 | WO |
| 2015026744 | Feb 2015 | WO |
| 2015065298 | May 2015 | WO |
| 2015082555 | Jun 2015 | WO |
| 2016154318 | Sep 2016 | WO |
| 2017030781 | Feb 2017 | WO |
| 2017166074 | May 2017 | WO |
| 2017091691 | Jun 2017 | WO |
| 2017165238 | Sep 2017 | WO |
| 2018081795 | May 2018 | WO |
| 2018171853 | Sep 2018 | WO |
| 2019022706 | Jan 2019 | WO |
| 2019204876 | Apr 2019 | WO |
| 2019143940 | Jul 2019 | WO |
| 2020185769 | Mar 2020 | WO |
| 2020075190 | Apr 2020 | WO |
| 2020130979 | Jun 2020 | WO |
| 2020149815 | Jul 2020 | WO |
| 2020229705 | Nov 2020 | WO |
| 2020245727 | Dec 2020 | WO |
| 2020249855 | Dec 2020 | WO |
| 2020252599 | Dec 2020 | WO |
| 2020256577 | Dec 2020 | WO |
| 2021021447 | Feb 2021 | WO |
| 2021022003 | Feb 2021 | WO |
| 2021038980 | Mar 2021 | WO |
| 2021055427 | Mar 2021 | WO |
| 2021055491 | Mar 2021 | WO |
| 2021061061 | Apr 2021 | WO |
| 2021081094 | Apr 2021 | WO |
| 2021090267 | May 2021 | WO |
| 2021138620 | Jul 2021 | WO |
| 2021216881 | Oct 2021 | WO |
| 2021236542 | Nov 2021 | WO |
| 2021236961 | Nov 2021 | WO |
| 2021262809 | Dec 2021 | WO |
| 2022047006 | Mar 2022 | WO |
| 2022092493 | May 2022 | WO |
| 2022092494 | May 2022 | WO |
| 2022212883 | Oct 2022 | WO |
| 2022212921 | Oct 2022 | WO |
| 2022216498 | Oct 2022 | WO |
| 2022251420 | Dec 2022 | WO |
| 2023008680 | Feb 2023 | WO |
| 2023008681 | Feb 2023 | WO |
| 2023022319 | Feb 2023 | WO |
| 2023022320 | Feb 2023 | WO |
| 2023052695 | Apr 2023 | WO |
| 2023091496 | May 2023 | WO |
| 2023215155 | Nov 2023 | WO |
| 2023230075 | Nov 2023 | WO |
| Entry |
|---|
| International Searching Authority, Search Report and Written Opinion for International Application No. PCT/US2021/038617, dated Oct. 15, 2021, 12 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2021/032807, dated Sep. 6, 2021, 11 pages. |
| Barrett et al., “Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care,” EPMA Journal (2019), pp. 445-464. |
| Oerkild et al., “Home-based cardiac rehabilitation is an attractive alternative to No. cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial,” BMJ Open Accessible Medical Research, Nov. 22, 2012, pp. 1-9. |
| Bravo-Escobar et al., “Effectiveness and safety of a home-based cardiac rehabilitation programme of mixed surveillance in patients with ischemic heart disease at moderate cardiovascular risk: A randomised, controlled clinical trial,” BMC Cardiovascular Disorders, 2017, pp. 1-11, vol. 17:66. |
| Thomas et al., “Home-Based Cardiac Rehabilitation,” Circulation, 2019, pp. e69-e89, vol. 140. |
| Thomas et al., “Home-Based Cardiac Rehabilitation,” Journal of the American College of Cardiology, Nov. 1, 2019, pp. 133-153, vol. 74. |
| Thomas et al., “Home-Based Cardiac Rehabilitation,” HHS Public Access, Oct. 2, 2020, pp. 1-39. |
| Dittus et al., “Exercise-Based Oncology Rehabilitation: Leveraging the Cardiac Rehabilitation Model,” Journal of Cardiopulmonary Rehabilitation and Prevention, 2015, pp. 130-139, vol. 35. |
| Chen et al., “Home-based cardiac rehabilitation improves quality of life, aerobic capacity, and readmission rates in patients with chronic heart failure,” Medicine, 2018, pp. 1-5 vol. 97:4. |
| Lima de Melo Ghisi et al., “A systematic review of patient education in cardiac patients: Do they increase knowledge and promote health behavior change?,” Patient Education and Counseling, 2014, pp. 1-15. |
| Fang et al., “Use of Outpatient Cardiac Rehabilitation Among Heart Attack Survivors—20 States and the District of Columbia, 2013 and Four States, 2015,” Morbidity and Mortality Weekly Report, vol. 66, No. 33, Aug. 25, 2017, pp. 869-873. |
| Beene et al., “AI and Care Delivery: Emerging Opportunities For Artificial Intelligence To Transform How Care Is Delivered,” Nov. 2019, American Hospital Association, pp. 1-12. |
| Jeong et al., “Computer-assisted upper extremity training using interactive biking exercise (iBikE) platform,” Sep. 2012, pp. 1-5, 34th Annual International Conference of the IEEE EMBS. |
| International Search Report and Written Opinion for PCT/US2023/014137, dated Jun. 9, 2023, 13 pages. |
| Website for “Esino 2022 Physical Therapy Equipments Arm Fitness Indoor Trainer Leg Spin Cycle Machine Exercise Bike for Elderly,” https://www.made-in-china.com/showroom/esinogroup/product-detailYdZtwGhCMKVR/China-Esino-2022-Physical-Therapy-Equipments-Arm-Fitness-Indoor-Trainer-Leg-Spin-Cycle-Machine-Exercise-Bike-for-Elderly.html, retrieved on Aug. 29, 2023, 5 pages. |
| Abedtash, “An Interoperable Electronic Medical Record-Based Platform For Personalized Predictive Analytics”, ProQuest LLC, Jul. 2017, 185 pages. |
| Alcaraz et al., “Machine Learning as Digital Therapy Assessment for Mobile Gait Rehabilitation,” 2018 IEEE 28th International Workshop on Machine Learning for Signal Processing (MLSP), Aalborg, Denmark, 2018, 6 pages. |
| Androutsou et al., “A Smartphone Application Designed to Engage the Elderly in Home-Based Rehabilitation,” Frontiers in Digital Health, Sep. 2020, vol. 2, Article 15, 13 pages. |
| Silva et al., “SapoFitness: A mobile health application for dietary evaluation,” 2011 IEEE 13th International Conference on U e-Health Networking, Applications and Services, Columbia, MO, USA, 2011, 6 pages. |
| Wang et al., “Interactive wearable systems for upper body rehabilitation: a systematic review,” Journal of NeuroEngineering and Rehabilitation, 2017, 21 pages. |
| Marzolini et al., “Eligibility, Enrollment, and Completion of Exercise-Based Cardiac Rehabilitation Following Stroke Rehabilitation: What Are the Barriers?,” Physical Therapy, vol. 100, No. 1, 2019, 13 pages. |
| Nijjar et al., “Randomized Trial of Mindfulness-Based Stress Reduction in Cardiac Patients Eligible for Cardiac Rehabilitation,” Scientific Reports, 2019, 12 pages. |
| Lara et al., “Human-Robot Sensor Interface for Cardiac Rehabilitation,” IEEE International Conference on Rehabilitation Robotics, Jul. 2017, 8 pages. |
| Ishraque et al., “Artificial Intelligence-Based Rehabilitation Therapy Exercise Recommendation System,” 2018 IEEE MIT Undergraduate Research Technology Conference (URTC), Cambridge, MA, USA, 2018, 5 pages. |
| Zakari et al., “Are There Limitations to Exercise Benefits in Peripheral Arterial Disease?,” Frontiers in Cardiovascular Medicine, Nov. 2018, vol. 5, Article 173, 12 pages. |
| You et al., “Including Blood Vasculature into a Game-Theoretic Model of Cancer Dynamics,” Games 2019, 10, 13, 22 pages. |
| Jeong et al., “Computer-assisted upper extremity training using interactive biking exercise (iBikE) platform,” Sep. 2012, 34th Annual International Conference of the IEEE EMBS, 5 pages. |
| Malloy, Online Article “AI-enabled EKGs find difference between numerical age and biological age significantly affects health, longevity”, Website: https://newsnetwork.mayoclinic.org/discussion/ai-enabled-ekgs-find-difference-between-numerical-age-and-biological-age-significantly-affects-health-longevity/, Mayo Clinic News Network, May 20, 2021, retrieved: Jan. 23, 2023, p. 1-4. |
| Jennifer Bresnick, “What is the Role of Natural Language Processing in Healthcare?”, pp. 1-7, published Aug. 18, 2016, retrieved on Feb. 1, 2022 from https://healthitanalytics.com/ featu res/what-is-the-role-of-natural-language-processing-in-healthcare. |
| Alex Bellec, “Part-of-Speech tagging tutorial with the Keras Deep Learning library,” pp. 1-16, published Mar. 27, 2018, retrieved on Feb. 1, 2022 from https://becominghuman.ai/part-of-speech-tagging-tutorial-with-the-keras-deep-learning-library-d7f93fa05537. |
| Kavita Ganesan, All you need to know about text preprocessing for NLP and Machine Learning, pp. 1-14, published Feb. 23, 2019, retrieved on Feb. 1, 2022 from https:// towardsdatascience.com/all-you-need-to-know-about-text-preprocessing-for-nlp-and-machine-learning-bcl c5765ff67. |
| Badreesh Shetty, “Natural Language Processing (NPL) for Machine Learning,” pp. 1-13, published Nov. 24, 2018, retrieved on Feb. 1, 2022 from https://towardsdatascience. com/natural-language-processing-nlp-for-machine-learning-d44498845d5b. |
| Gerbild et al., “Physical Activity to Improve Erectile Dysfunction: A Systematic Review of Intervention Studies,” Sexual Medicine, 2018, 15 pages. |
| Davenport et al., “The Potential For Artificial Intelligence In Healthcare”, 2019, Future Healthcare Journal 2019, vol. 6, No. 2: Year: 2019, pp. 1-5. |
| Ahmed et al., “Artificial Intelligence With Multi-Functional Machine Learning Platform Development For Better Healthcare And Precision Medicine”, 2020, Database (Oxford), 2020:baaa010. doi: 10.1093/database/baaa010 (Year: 2020), pp. 1-35. |
| Ruiz Ivan et al., “Towards a physical rehabilitation system using a telemedicine approach”, Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization, vol. 8, No. 6, Jul. 28, 2020, pp. 671-680, XP055914810. |
| De Canniere Helene et al., “Wearable Monitoring and Interpretable Machine Learning Can Objectively Track Progression in Patients during Cardiac Rehabilitation”, Sensors, vol. 20, No. 12, Jun. 26, 2020, XP055914617, pp. 1-15. |
| Boulanger Pierre et al., “A Low-cost Virtual Reality Bike for Remote Cardiac Rehabilitation”, Dec. 7, 2017, Advances in Biometrics: International Conference, ICB 2007, Seoul, Korea, pp. 155-166. |
| Yin Chieh et al., “A Virtual Reality-Cycling Training System for Lower Limb Balance Improvement”, BioMed Research International, vol. 2016, pp. 1-10. |
| Website for “Pedal Exerciser”, p. 1, retrieved on Sep. 9, 2022 from https://www.vivehealth.com/collections/physical-therapy-equipment/products/pedalexerciser. |
| Website for “Functional Knee Brace with ROM”, p. 1, retrieved on Sep. 9, 2022 from http://medicalbrace.gr/en/product/functional-knee-brace-with-goniometer-mbtelescopicknee/. |
| Website for “ComfySplints Goniometer Knee”, pp. 1-5, retrieved on Sep. 9, 2022 from https://www.comfysplints.com/product/knee-splints/. |
| Website for “BMI FlexEze Knee Corrective Orthosis (KCO)”, pp. 1-4, retrieved on Sep. 9, 2022 from https://orthobmi.com/products/bmi-flexeze%C2%AE-knee-corrective-orthosis-kco. |
| Website for “Neoprene Knee Brace with goniometer—Patella Rom MB.4070”, pp. 1-4, retrieved on Sep. 9, 2022 from https://www.fortuna.com.gr/en/product/neoprene-knee-brace-with-goniometer-patella-rom-mb-4070/. |
| Kuiken et al., “Computerized Biofeedback Knee Goniometer: Acceptance and Effect on Exercise Behavior in Post-total Knee Arthroplasty Rehabilitation,” Biomedical Engineering Faculty Research and Publications, 2004, pp. 1-10. |
| Ahmed et al., “Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine,” Database, 2020, pp. 1-35. |
| Davenport et al., “The potential for artificial intelligence in healthcare,” Digital Technology, Future Healthcare Journal, 2019, pp. 1-5, vol. 6, No. 2. |
| Website for “OxeFit XS1”, pp. 1-3, retrieved on Sep. 9, 2022 from https://www.oxefit.com/xs1. |
| Website for “Preva Mobile”, pp. 1-6, retrieved on Sep. 9, 2022 from https://www.precor.com/en-us/resources/introducing-preva-mobile. |
| Website for “J-Bike”, pp. 1-3, retrieved on Sep. 9, 2022 from https://www.magneticdays.com/en/cycling-for-physical-rehabilitation. |
| Website for “Excy”, pp. 1-12, retrieved on Sep. 9, 2022 from https://excy.com/portable-exercise-rehabilitation-excy-xcs-pro/. |
| Website for “OxeFit XP1”, p. 1, retrieved on Sep. 9, 2022 from https://www.oxefit.com/xp1. |
| Chrif et al., “Control design for a lower-limb paediatric therapy device using linear motor technology,” Article, 2017, pp. 119-127, Science Direct, Switzerland. |
| Robben et al., “Delta Features From Ambient Sensor Data are Good Predictors of Change in Functional Health,” Article, 2016, pp. 2168-2194, vol. 21, No. 4, IEEE Journal of Biomedical and Health Informatics. |
| Kantoch et al., “Recognition of Sedentary Behavior by Machine Learning Analysis of Wearable Sensors during Activities of Daily Living for Telemedical Assessment of Cardiovascular Risk,” Article, 2018, 17 pages, Sensors, Poland. |
| Warburton et al., “International Launch of the Par—•Q+ and ePARmed—•X+ Validation of the PAR—•Q+ and ePARmed••X+,” Health & Fitness Journal of Canada, 2011, 9 pages, vol. 4, No. 2. |
| Number | Date | Country | |
|---|---|---|---|
| 20210134463 A1 | May 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62910232 | Oct 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17021895 | Sep 2020 | US |
| Child | 17146694 | US |
